document incorporate reference specify portion registrant proxy statement file commission pursuant regulation connection registrant annual meeting stockholder hold incorporate reference iii report base closing price share june exclude share registrant common stock hold executive officer director stockholder ownership exceed registrant common stock outstanding june exclusion share construe indicate person possess power direct indirect direct cause direction management policy registrant person control common control registranttable content gilead sciences inc annual report table content item business item risk factor item b unresolved staff comment item property item legal proceeding item submission matter vote security holder ii item market registrant common equity relate stockholder matter issuer purchase equity security item select financial datum item management discussion analysis financial condition result operation item quantitative qualitative disclosure market risk item financial statement supplementary datum item change disagreement accountant account financial disclosure item control procedure item b information iii item director executive officer corporate governance item executive compensation item security ownership certain beneficial owner management relate stockholder matter item certain relationship relate transaction director independence item principal accountant fee service iv item exhibit financial statement schedule signature right trademark copyright trade name business include follow gilead science hepsera viread vistide ambisome emtriva truvada atripla register trademark belong bristolmyer squibb gilead sciences llc macugen register trademark belong osi pharmaceuticals inc sustiva register trademark bristolmyer squibb company tamiflu register trademark belong f hoffmannla roche ltd flolan register trademark glaxosmithkline inc report include trademark service mark trade name companiestable content annual report include section entitle management discussion analysis financial condition result operation contain forward look statement future event future result subject safe harbor create security act amend securities act securities exchange act amended exchange act word expect anticipate target goal project intend plan believe seek estimate continue variation word similar expression intend identify forwardlooke statement addition statement refer projection future financial performance anticipate growth trend business characterization future event circumstance forwardlooke statement base forward look statement current expectation future event statement guarantee future performance involve risk uncertainty assumption difficult predict actual result differ materially suggest forward look statement reason include identify risk factor beginning give risk uncertainty caution place undue reliance forward look statement forward look statement include report date hereof require federal security law rule regulation securities exchange commission sec undertake specifically decline obligation update statement publicly announce result revision forward look statement distribution report result new information future event change assumption item business overview gilead sciences inc gilead incorporate delaware june biopharmaceutical company discover develop commercialize innovative therapeutic area unmet medical need mission advance care patient suffer lifethreatening disease worldwide headquarter foster city california operations north america europe australia date focus effort bring market novel therapeutic treatment lifethreatene infectious disease expand research development commercial focus include respiratory cardiopulmonary disease acquisition company continue seek add exist portfolio product internal discovery clinical development program active product acquisition inlicense strategy acquire follow company respiratory cardiopulmonary disease area august acquire corus pharma inc corus company engage drug discovery relate respiratory infectious disease coruss lead product candidate aztreonam lysine inhalation inhale antibiotic activity gramnegative bacteria include pseudomona aeruginosa cause lung infection patient cystic fibrosis cf complete enrollment second phase study january expect datum study midyear pende positive outcome second phase study anticipate file new drug application nda food drug administration fda regulatory approval aztreonam lysine treatment cf united states second half addition aztreonam lysine explore inhale compound treatment respiratory infection november acquire myogen inc myogen company engage primarily drug discovery relate cardiopulmonary disease cardiovascular disorder myogen lead product candidate ambrisentan endothelin receptor antagonist potential treatment pulmonary arterial hypertension pah december file nda treatment pah ambrisentan table content fda february fda grant priority review status nda marketing approval ambrisentan establish target review date june ambrisentan grant orphan drug status potential treatment pah united states european union exclusive right ambrisentan united states glaxosmithkline inc gsk hold exclusive right ambrisentan territory outside united states products truvada tenofovir disoproxil fumarate emtricitabine oral formulation dose day combination therapy treat human immunodeficiency virus hiv infection adult fixeddose combination antihiv medication viread tenofovir disoproxil fumarate emtriva emtricitabine promote truvada united states commercial team sell united states exclusively wholesale channel promote sell truvada european union commercial team distributor australia new zealand commercial team certain latin american country distributor promote sell truvada japan corporate partner japan tobacco inc japan tobacco addition truvada available noprofit price certain develop world country include gilead access program exclusive worldwide license patent right relate technology viread emtriva component truvada institute organic chemistry biochemistry academy sciences czech republic rega stichting vzw iocbrega emory university emory respectively viread oral formulation nucleotide analogue reverse transcriptase inhibitor dose day combination therapy treat hiv infection adult promote viread united states commercial team sell united states exclusively wholesale channel promote sell viread european union commercial team distributor australia new zealand commercial team certain latin american country distributor promote sell viread japan corporate partner japan tobacco addition viread available noprofit price certain develop world country include gilead access program exclusive worldwide license patent right relate technology viread iocbrega atripla efavirenz mg emtricitabine mg tenofovir disoproxil fumarate mg oral formulation dose day treatment hiv infection adult atripla oncedaily single tablet regimen hiv intend standalone therapy combination antiretroviral fixeddose combination antihiv medication viread emtriva bristol myerssquibb company sustiva efavirenz atripla approve commercial sale united states promote atripla joint venture partner bristol myerssquibb company bms united states company commercial team sell joint venture bms bristol myers squibb gilead sciences llc united states exclusively wholesale channel exclusive worldwide license patent right relate technology viread emtriva component atripla iocbrega emory respectively sustiva component atripla license joint venture bms file marketing approval atripla european union bms merck co inc merck october threeway joint venture establish company emtriva oral formulation nucleoside analogue reverse transcriptase inhibitor dose day combination therapy treat hiv infection adult united states europe emtriva approve combination therapy treat hiv infection child promote emtriva united states commercial team sell united states exclusively wholesale channel promote sell emtriva european union commercial team distributor australia new zealand commercial team certain latin american country distributor promote sell emtriva table content japan corporate partner japan tobacco exclusive worldwide license patent right relate technology emtriva emory hepsera adefovir dipivoxil oral formulation nucleotide analogue hepatitis b virus hbv dna polymerase inhibitor dose day treat chronic hepatitis b hepsera approve sale united states treatment chronic hepatitis b adult evidence active viral replication evidence persistent elevation serum aminotransferase alt ast histologically active liver disease commercial team promote hepsera united states sell united states exclusively wholesale channel promote sell hepsera european union commercial team distributor australia new zealand commercial team license right commercialize hepsera solely treatment hepatitis b asia latin america certain territory gsk begin sell hepsera japan republic korea taiwan china subject obligation pay royalty net sale gsk generate hespera exclusive worldwide license patent right relate technology hepsera iocbrega ambisome amphotericin b liposome injection proprietary liposomal formulation amphotericin b antifungal agent treat invasive fungal infection cause fungal specie corporate partner astellas pharma inc astellas promote sell ambisome united states canada promote sell ambisome europe australia new zealand international commercial team use distributor promote sell ambisome latin america south america asia japan dainippon sumitomo pharma co ltd handles promotion distribution india mediterranean middle east vistide cidofovir injection antiviral medication treatment cytomegalovirus retinitis patient acquire immunodeficiency syndrome aid vistide approve sale united states promote vistide united states commercial team sell united states exclusively wholesale channel country outside united states vistide sell pfizer inc pfizer subject obligation pay royalty net sale pfizer generate vistide flolan epoprostenol sodium inject medication longterm intravenous treatment primary pulmonary hypertension pulmonary hypertension associated scleroderma spectrum disease new york heart association class iii class iv patient respond adequately conventional therapy march myogen acquire november enter license agreement distribution supply agreement gsk exclusive right market promote distribute flolan sterile diluent flolan united states april follow table list aggregate product sale major product thousand total total total product product product sale sale sale hiv product truvada viread atripla emtriva total hiv product sale hepsera ambisome total product sale table content item note consolidated financial statement page include annual report product sale geographic area royalty product tamiflu oseltamivir phosphate oral antiviral available capsule form treatment prevention influenza b tamiflu class prescription drug call neuraminidase inhibitor tamiflu approve treatment influenza child adult country include united states japan european union approve prevention influenza child adults united states japan european union develop tamiflu f hoffmannla roche ltd hoffmannla roche inc roche roche exclusive right manufacture party sell tamiflu worldwide subject obligation pay royalty base percentage net sale roche generate tamiflu worldwide macugen pegaptanib sodium injection intravitreal injection antiangiogenic oligonucleotide treatment neovascular agerelate macular degeneration macugen approve fda united states december sale commence january february product receive marketing approval sale european union macugen develop osi pharmaceuticals inc osi technology license promote united states osi pfizer osi hold exclusive right manufacture sell macugen worldwide subject osis obligation pay royalty base percentage net sale osi generate macugen worldwide daunoxome liposomal daunorubicin injection liposomal formulation anticancer agent daunorubicin approve sale united states europe certain country treatment aidsrelate kaposis sarcoma march exclusively license worldwide right sell daunoxome diato sa diato term license agreement diato obligate pay royalty base percentage net sale diato generate daunoxome commercialization distribution international commercial sale operation marketing subsidiary australia austria belgium canada france germany greece ireland italy netherlands new zealand portugal spain switzerland turkey united kingdom united states commercial team promote truvada viread emtriva hepsera direct field contact physician hospital clinic healthcare provider involve treatment patient hiv truvada viread emtriva chronic hepatitis b hepsera sell truvada viread emtriva hepsera united states exclusively wholesale channel corporate partner astella promote sell ambisome united states sell truvada viread emtriva hepsera ambisome european union commercial team distributor australia new zealand commercial team promote atripla united states joint venture partner bms respective commercial team direct field contact physician hospital clinic healthcare provider involve treatment patient hiv promote vistide united states commercial team sell united states exclusively wholesale channel commercial team promote distribute flolan sterile diluent flolan united states promote sell distribute product country outside united states european union include country asia latin america middle east africa certain territory enter table content agreement thirdparty distributor grant exclusive right sell product particular territory specify period time agreement provide collaborative effort distributor obtain regulatory approval product specify territory agreement generally grant distributor right market product territory march initiate evaluation european distribution framework outside exist european subsidiary result initiate contact certain european distributor intent ultimately terminate distribution agreement product sale large wholesaler account total revenue year end december combine basis wholesaler account approximately product sale united states follow table summarize percent total revenue attribute sale wholesaler year end december cardinal health inc mckesson corp amerisourcebergen corp competition product development program target number area include viral fungal respiratory cardiopulmonary disease commercially available product treatment disease large number company institution spend considerable amount money resource develop additional product treat disease product compete available product base primarily efficacy safety tolerability acceptance doctor ease patient compliance patent protection ease use price insurance reimbursement coverage distribution marketing hiv product hiv landscape competitive complex treatment trend continue evolve grow number antihiv drug currently sell advanced stage clinical development approximately brand drug available united states hiv product primarily compete fixeddose combination product nucleotidenucleoside reverse transcriptase inhibitor nrti class include combivir lamivudine zidovudine epzicom abacavir lamivudine trizivir abacavirlamivudinezidovudine sell gsk company hiv product compete nrti class include bms roche hiv product compete broadly hiv product boehringer ingelheim gmbh merck abbott laboratories inc tibotec therapeutic division ortho biotech product lp table content bmss videx ec didanosine ddi generic hiv product united states gsk retrovir zidovudine face generic competition united states result launch generic zidovudine date little impact generic didanosine generic zidovudine price hiv product price decrease hiv product result long term ambisome ambisome face strong competition current expect competitor competition current expect competitor erode revenue receive sale ambisome ambisome primarily compete vfend voriconazole develop pfizer caspofungin product develop merck market cancidas united states caspofungin ambisome compete lipidbase amphotericin b product include abelcet amphotericin b lipid complex injection sell enzon pharmaceuticals inc united states canada japan zeneus pharma ltd europe amphotec amphotericin b cholesteryl sulfate complex injection sell river pharmaceutical llc worldwide anfogen amphotericin b liposomal sell genpharma sa argentina bms numerous generic manufacturer sell conventional amphotericin b compete ambisome aware report lipid formulation claim similarity ambisome available outside united states include anticipate entry formulation greece addition amphiprol amphotericin b proel pharmaceutical approve commercially available greece formulation reduce market demand ambisome furthermore manufacture lipid formulation amphotericin b complex formulation find unsafe sale ambisome negatively impact association hepsera hepsera face significant competition exist expect therapy treat patient infect hbv hepsera compete primarily antiviral product baraclude entecavir oral nucleoside analogue develop bms launch united states tyzeka telbivudine oral nucleoside analogue develop novartis pharmaceutical corporation novartis idenix pharmaceutical limited idenix launch united states october epivirhbvzeffix lamivudine develop gsk collaboration shire pharmaceuticals group plc sell major country north south america europe asia hepsera face competition clinicalstage candidate include pradefovir mesylate oral antiviral compound develop valeant pharmaceutical international currently phase clinical trial hepsera competes establish immunomodulatory therapy include introna interferon alfab sell schere plough corporation major country north south america europe asia pegasys pegylate interferon alfaa injectable drug similar introna sell roche treatment hbv vistide vistide compete number drug treat cytomegalovirus retinitis include cytovene iv cytovene ganciclovir sell intravenous oral formulation roche ocular implant bausch lomb incorporate valcyte valganciclovir market roche foscavir foscarnet intravenous drug sell astrazeneca plc vitravene fomivirsen drug inject directly eye sell cibavision tamiflu tamiflu compete relenza zanamivir antiinfluenza drug sell gsk relenza neuraminidase inhibitor deliver orallyinhale dry powder generic competitor include amantadine rimantadine oral tablet inhibit replication influenza virus biocryst pharmaceuticals inc develop injectable formulation peramivir influenza neuraminidase inhibitor treatment influenza currently phase clinical trial macugen macugen compete primarily visudyne verteporfin injection sell novartis connection photodynamic therapy lucentis ranibizumab sell genentech inc table content flolan flolan compete primarily remodulin treprostinil form prostacyclin administer continuous subcutaneous infusion continuous intravenous infusion sell united therapeutics corporation united states flolan compete ventavis iloprost inhale form prostacyclin sell affiliate actelion ltd united states addition generic pharmaceutical company launch attempt launch generic version flolan united states number company pursue development technology competitive research program compete company include specialized pharmaceutical firm large pharmaceutical company act independently biopharmaceutical company furthermore academic institution government agency public private organization conduct research seek patent protection establish collaborative arrangement competitive product program anticipate face increase competition future competitor introduce new product market new technology available determine exist product new product competitor develop effective effectively market sell develop competitive product render technology product obsolete noncompetitive recover investment resource develop product collaborative relationship business strategy establish collaboration company university medical research institution assist clinical development andor commercialization certain product product candidate provide support research program evaluate opportunity acquire product right product technology complementary business company university medical research institution information relationship include financial accounting impact business find item note consolidated financial statement page include annual report commercial collaboration follow list representative commercial collaboration year commercial collaboration partner program area sign emory emtricitabine bristol myerssquibb atripla japan tobacco viread truvada emtriva gsk hepsera flolan osi liposome product macugen pfizer macugen vistide sumitomo ambisome roche tamiflu md anderson cancer center hepsera iocbrega atripla viread truvada hepsera vistide astella ambisome ulehi selex emory university emory april triangle pharmaceuticals inc triangle acquire january obtain exclusive worldwide license emorys right purify form emtricitabine use hiv hbv indication prior july pay royalty emory respect worldwide net sale product contain emtricitabine july royalty pharma purchase respectively royalty interest own emory exchange elimination emtricitabine royalty payable emory july pay table content royalty respect worldwide net sale product contain emtricitabine directly royalty pharma rate proportional share purchase price july payment emory connection amendment restatement exist license agreement emory pertain obligation develop emtricitabine hepatitis b indication bristolmyers squibb company bms december enter collaboration bms develop commercialize single tablet regimen truvada bmss sustiva united states combination approve use united states july sell atripla bms structure collaboration joint venture form limited liability company call bristolmyers squibb gilead sciences llc term collaboration bms grant royaltyfree sublicense joint venture use respective companyowne technology return grant license joint venture use intellectual property result collaboration economic interest joint venture hold bms base fraction estimate net selling price atripla attributable truvada sustiva respectively adjust annual basis net selling price truvada change time relative net selling price sustiva bmss respective economic interest joint venture vary annually bms share marketing sale effort party provide equivalent sale force effort minimum number year daily operation joint venture govern primary joint committee responsible accounting financial reporting product distribution joint venture september bms amend joint venture collaboration agreement allow joint venture sell atripla canada japan tobacco inc japan tobacco july enter licensing agreement japan tobacco japan tobacco commercialize hiv product portfolio specifically viread truvada emtriva japan term agreement receive upfront license fee receive additional cash payment achievement certain milestone japan tobacco require pay royalty net sale product japan march viread approve sale japan march emtriva truvada approve sale japan glaxosmithkline inc gsk march myogen acquire november enter license distribution supply agreement gsk exclusive right market promote distribute flolan sterile diluent flolan united states april gsk assign right responsibility respect flolan certain agreement specialty pharmacy distributor extent gross sale flolan united state exceed certain predefine target supply price pay gsk flolan decrease slide scale myogen commence distribution activity flolan united states distribution supply agreement april april enter licensing agreement gsk provide gsk right commercialize hepsera solely treatment chronic hepatitis b asia latin america certain territory significant include china japan republic korea taiwan agreement retain right hepsera united states canada europe australia new zealand turkey receive upfront license fee milestone payment payable licensing agreement gsk responsibility development commercialization hepsera treatment hepatitis b territory addition gsk require pay royalty net product sale hepsera gsk hepatitis product epivirhbvzeffix gsk territory hepsera launch japan republic korea taiwan china osi pharmaceuticals inc osi december complete sale oncology asset osi term agreement entitle additional payment osi cash combination cash osi stock osi reach certain development milestone nx advanced oncology product candidate sell osi table content relate manufacturing agreement produce nx gs l liposomal drug candidate include sale march enter agreement osi successor eyetech pharmaceuticals inc relate macugen term agreement osi worldwide right therapeutic use macugen responsible research development cost entitle receive payment osi osi reach certain milestone royaltie worldwide net sale macugen december enter agreement osi fill finish macugen osi initial term end january pfizer inc pfizer december osi grant pfizer sublicense relate macugen connection sublicense enter license pfizer term contain agreement osi macugen approve fda united states december sale commence january february product receive marketing approval sale european union august enter agreement pfizer successor pharmacia corporation relate vistide agreement pfizer exclusive right market sell vistide country outside united states subject payment percentage net product sale agreement require sell pfizer bulk cidofovir maintain vistide patent connection agreement receive upfront license fee cash payment obtain marketing approval europe certain royalty net sale vistide dainippon sumitomo pharma co ltd sumitomo september enter agreement sumitomo pursuant sumitomo agree develop market ambisome japan term agreement receive upfront license fee addition entitle receive additional payment certain clinical commercial milestone meet receive royalty ambisome sale japan f hoffmannla roche ltd hoffmannla roche inc roche september enter development license agreement roche develop commercialize therapy treat prevent viral influenza tamiflu antiviral oral formulation treatment prevention influenza codevelope roche original agreement roche exclusive right manufacture sell tamiflu worldwide subject obligation pay percentage net sale roche generate tamiflu sale november enter amendment supplement original agreement roche amendment eliminate cost good adjustment royalty calculation retroactive calendar year future calculation amendment provide formation joint manufacturing committee review roche exist manufacturing capacity tamiflu global plan manufacture tamiflu commercial committee evaluate commercial plan strategy tamiflu united states joint supervisory committee evaluate roche overall commercial plan tamiflu global basis committee consist representative roche amendment option provide specialized sale force supplement roche marketing effort tamiflu md anderson cancer center enter agreement md anderson cancer center relate hepsera connection agreement pay upfront license fee require pay md anderson cancer center percentage net sale base sales hepsera institute organic chemistry biochemistry academy sciences czech republic rega stichte iocbrega enter agreement iocbrega relate certain nucleotide compound discover institution agreement receive exclusive right manufacture use sell nucleotide compound obligate pay iocbrega percentage net sale receive sale product contain patented compound subject minimum royalty payment product cover table content original agreement include vistide hepsera viread december agreement iocbrega amend provide reduce royalty rate future sale product incorporate adefovir active ingredient hepsera tenofovir active ingredient viread truvada return upfront payment sign amendment august agreement iocbrega amend include truvada future fixeddose combination product contain license technology iocbrega agree waive right royalty sale truvada viread develop country sell product profit access program sale atripla distribute merck develop country august execute amendment iocbrega set forth royalty obligation sale tenofovir certain upper low middle income country sale tenofovir manufacture indian generic company certain specify develop country include india astellas pharma inc astellas enter agreement astella successor fujisawa usa inc relate right market ambisome agreement amend astella responsible promotion ambisome united states astellas sole marketing right ambisome canada exclusive marketing right ambisome rest world subject obligation pay royalty astellas connection sale significant market asia include china india japan republic korea taiwan astellas collect payment sale ambisome united states canada entitle receive royalty base specified percentage astellass gross profit sale ambisome united states canada university license equity holdings inc ulehi ongoing collaborative arrangement ulehi successor university technology corporation predecessor university research corporation technology hold company university colorado boulder relate identification aptamer oligonucleotide diagnostic therapeutic application selex technology arrangement ulehi grant present future right invention cover patent patent application selex technology improvement selex technology make discover oligonucleotide molecule make selex technology computer software relate selex technology require pay ulehi royalty base revenue generate sale product derive selex technology include revenue base license agreement osi relate macugen ulehi assign royalty income capital royalty partner lp pursuant consent agreement sign connection assignment pay royalty obligation relate selex process patent capital royalty partner lp develop world collaboration december establish gilead access program pursuant agree truvada viread available noprofit price develop country africa caribbean latin america southeast asia step ensure viread truvada sell program serve patient develop world divert market utilize different trade dress european tablet follow list representative develop world collaboration international partnership microbicide ipm conrad december enter agreement grant right ipm conrad cooperate agency agency international development usaid committed improve reproductive health expand contraceptive choice woman man develop manufacture prove efficacious arrange distribution resourcelimite country tenofovir microbicide prevent infection hiv table content merck august enter agreement affiliate merck pursuant working merck provide low cost atripla hivinfecte patient develop country africa caribbean latin america southeast asia utilize different trade dress european tablet agreement manufacture atripla efavirenz supply merck merck handle distribution product country cover agreement generic license enter nonexclusive license agreement indian generic manufacturer grant right produce distribute generic version tenofovir lowincome country world include india lowincome country gilead access program agreement require generic manufacturer meet certain national international regulatory standard include technology transfer enable expeditious production large volume high quality generic version tenofovir addition agreement allow manufacture commercial quantity active pharmaceutical ingredient finish product aspen pharmacare october enter nonexclusive manufacture distribution agreement aspen pharmacare provide manufacture distribution viread truvada certain develop world country include gilead access program bill melinda gates foundation gates foundation family health international fhi december enter agreement gate foundation fhi provide viread fhis multinational clinical trial evaluate viread effectiveness method reduce risk hiv infection sexually active adult regularly expose hiv clinical trial conduct fhi funded million grant gate foundation clinical trial complete march institute world health january enter agreement institute world health pursuant provide ambisome cost phase clinical trial evaluate ambisome treatment visceral leishmaniasis paromomycin india great global burden visceral leishmaniasis exist clinical trial conduct institute world health partnership world health organization dart study november enter collaborative agreement medical research council mrc united kingdom boehringer ingelheim gmbh gsk connection fiveyear clinical study conduct mrc antiretroviral hiv therapy africa trial call dart study development antiretroviral therapy aim study clinical versus laboratory monitoring practice structure treatment interruption continuous antiretroviral therapy adult hiv infection subsaharan africa provide viread cost dart study table content research collaboration follow list representative research collaboration research collaboration partner program area year sign japan tobacco gs know jtk treatment hiv achillion gs know ach relate compound treatment hcv genelab nucleoside rna polymerase inhibitor treatment hcv novartis vaccine small molecule therapeutic certain hcv drug target glaxosmithkline ambrisentan treatment certain hypertensive condition novartis institute novel compound treatment cardiovascular disease abbott laboratories ambrisentan darusentan treatment certain hypertensive condition university texas novel compound treatment cardiac hypertrophy heart failure japan tobacco march enter licensing agreement japan tobacco japan tobacco grant exclusive right develop commercialize novel hiv integrase inhibitor gs know jtk country world exclude japan japan tobacco retain right term agreement pay upfront license fee milestone payment additionally obligate additional cash payment achievement certain milestone pay royalty base future net product sale territory market drug achillion pharmaceuticals inc achillion november enter exclusive license collaboration agreement achillion pursuant agreement grant worldwide right research development commercialization certain small molecule hcv replication inhibitor involve hcv protease treatment hepatitis c collaboration achillion obligate continue development inhibitor compound accord mutually agree development plan completion proofofconcept clinical study hcvinfecte patient cost incur achieve proofofconcept share equally achillion contractually agree budget follow proofofconcept study obligate assume responsibility incur cost associate development commercialization compound warrant development achillion option participate commercialization effort future product arise collaboration conjunction signing collaboration pay upfront license fee certain investment achillion equity agree payment achillion achievement certain milestone outline agreement pay royalty future net sale product arise collaboration december achillion begin dose hcv infected patient phase clinical study gs know ach treatment hepatitis c february base preliminary datum phase b study company decide discontinue development gs genelabs technologies inc genelabs september enter license research collaboration agreement genelab research develop commercialize certain genelabss novel nucleoside inhibitor hcv polymerase treatment chronic infection cause hcv conjunction signing agreement pay upfront license fee initial term year term extend additional year option genelab obligate table content lead research effort agree provide annual research payment fund fulltime equivalent lead development commercialization activity obligate additional payment achievement certain milestone pay royalty future net sale select compound develop approve relation collaboration novartis vaccine diagnostic inc novartis vaccine august enter nonexclusive licensing agreement novartis vaccine successor chiron corporation research development commercialization small molecule therapeutic select hcv drug target agreement receive nonexclusive right use novartis vacciness hcv technology develop commercialize product treatment hcv term agreement pay novartis vaccine upfront license fee agree additional payment certain clinical regulatory contractually determined milestone meet additionally obligate royalty payment event product develop licensed technology glaxosmithkline gsk march myogen acquire november enter license agreement gsk gsk receive exclusive sublicense right ambrisentan certain hypertensive condition territory outside united states license agreement myogen receive upfront payment subject achievement specific milestone eligible receive additional milestone payment addition receive step royalty base net commercial sale ambrisentan gsk territory gsk option negotiate exclusive sublicense additional therapeutic use ambrisentan gsk territory term license agreement agreement continue conduct bear expense clinical development activity believe required obtain maintain regulatory approval ambrisentan united states canada european economic area party conduct additional development activity territory expense party agree jointly develop ambrisentan new indication license field party pay share external cost associate joint development novartis institutes biomedical research inc novartis institutes october myogen enter research collaboration novartis institute discovery development novel drug treatment cardiovascular disease novartis institute provide research fund exchange right license compound develop collaboration collaboration expand include myogen histone deacetylase inhibitor hdaci program novartis institute exclusive option discovery relevant field limited exception relate hdaci product candidate october relate product candidate hdaci product candidate execution license product candidate novartis institute obligate fund development product candidate payment achievement certain milestone pay royalty sale product successfully commercialize date novartis institutes license drug target compound term collaboration abbott laboratories inc abbott october myogen enter license agreement abbott successfully develop ambrisentan pah require additional milestone payment pay royalty base net sale ambrisentan fail commercialize ambrisentan certain market abbott market product affect market pay royalty sale december file nda fda treatment pah ambrisentan march myogen license right commercialize ambrisentan territory outside united states gsk june myogen enter exclusive worldwide license agreement abbott develop commercialize darusentan condition oncology obligate future milestone payment pay royalty base net sale successfully commercialize drug indication commercialize darusentan certain market abbott market product affect market pay royalty sale darusentan table content currently study clinical trial treatment patient resistant hypertension university texas system december myogen enter license agreement university texas system provide exclusive right certain patent technology relate cardiac hypertrophy heart failure concurrently enter sponsor research agreement university fund research cardiac hypertrophy heart failure university texas southwestern medical center agreement right invention arise sponsor research obligate pay future annual fee begin year follow termination sponsor research agreement percentage sublicense revenue royalty base net sale additionally obligate milestone payment drug develop license technology january myogen enter second license agreement amend february relate sponsor research agreement university texas system agreement receive exclusive right certain patent technology relate cardiac hypertrophy heart disease heart failure include invention arise conduct sponsor research obligation pay milestone payment plus percentage sublicense revenue royalty base percentage net sale sponsor research agreement enter concurrently license agreement obligate annual payment university march research development addition enter collaboration company university medical research institution seek add exist portfolio product internal discovery clinical development program active licensing product acquisition strategy acquisition myogen corus year research scientist foster city san dimas california durham north carolina seattle washington westminster colorado engage discovery development new molecule technology hope lead new medicine novel formulation exist drug internal research focus discovery development treatment disease follow area hiv february announce complete phase study gs novel hiv integrase inhibitor license japan tobacco clinical study meet primary endpoint noninferiority viral load reduction hivpositive patient begin design phase study pende discussion fda commence second quarter integrase inhibitor represent relatively new class compound long history clinical research development face challenge clinical trial protocol design trial enrollment result clinical trial involve integrase inhibitor predictable drug candidate treatment hiv hepatitis hbv june complete enrollment phase study compare efficacy safety tenofovir disoproxil fumarate active pharmaceutical ingredient viread versus hepsera patient infect hepatitis b anticipate data study second half pende positive outcome study anticipate file regulatory approval tenofovir disoproxil fumarate treatment hepatitis b united states european union prior end table content hcv december collaboration partner achillion begin dose patient gs know ach small molecule inhibitor hcv phase viral dynamic study goal trial evaluate pharmacokinetic tolerability safety multiple escalate dose gs hcvinfecte patient february base preliminary datum study company decide discontinue development gs treatment hcv infection fourth quarter begin dose hcvinfecte patient phase study gs nonnucleoside polymerase inhibitor anticipate safety efficacy datum study second quarter respiratory cardiopulmonary disease expand research development focus include respiratory cardiopulmonary disease acquisition corus august acquisition myogen november december announce phase aircf study aztreonam lysine inhalation treatment people cf pulmonary pseudomona aeruginosa meet primary efficacy endpoint time need inhale intravenous antibiotic assess onset common symptom predictive pulmonary exacerbation complete enrollment second phase study january expect datum study midyear pende positive outcome second study anticipate file regulatory approval aztreonam lysine inhalation treatment cf united states second half addition aztreonam lysine inhalation explore inhale compound treatment respiratory infection december complete submission nda fda marketing approval ambrisentan oncedaily treatment pah february fda grant priority review status nda marketing approval ambrisentan establish target review date june june initiate phase clinical trial evaluate darusentan patient resistant hypertension study enrol slowly evaluate certain modification studys protocol follow discussion regulatory authority implement increase enrollment rate study intend begin enrollment second phase study year addition research collaboration agreement novartis institute focus identification diseasemodifye drug treatment chronic heart failure relate cardiovascular disorder total research development expense million compare million million patent proprietary right patent proprietary right important business properly design enforceable patent difficult competitor use technology create competitive product difficult competitor obtain patent prevent technology create business strategy actively seek patent protection united states internationally file additional patent application appropriate cover improvement compound product technology rely trade secret internal knowhow technological innovation agreement party develop maintain protect competitive position ability competitive depend success strategy number foreign patent patent application right patent relate compound product technology certain issue patent enforceable provide adequate protection pende patent application result issue patent table content follow table show actual estimate expiration date united states europe primary patent patent issue pende application cover compound market product european patent patent product expiration expiration daunoxome vistide hepsera ambisome tamiflu macugen viread emtriva truvada atripla patent cover truvada viread atripla emtriva hepsera vistide hold party acquire exclusive right patent agreement party commercial collaboration patent cover active ingredient ambisome instead hold patent liposomal formulation compound protect formulation trade secret patent filing cover form adefovir dipivoxil active ingredient hepsera china certain country asia application pende country asia include china relate specific form formulation hepsera asia major market impact hepatitis b indication hepsera develop addition flolan patent hold party market exclusivity protection expired result generic pharmaceutical company launch attempt launch generic version flolan united states obtain patent certain product year obtain marketing approval product patent limited life begin run prior commercial sale relate product commercial value patent limit able apply patent term extension example extension patent vistide grant united states number european country compensate delay obtain marketing approval similar patent term extension available product develop certain obtain important infringe patent proprietary right violate agreement grant proprietary right infringe patent violate agreement prevent develop selling product process cover patent agreement require obtain license party allow use technology certain require obtain license thirdparty technology obtain reasonable cost able obtain require license adversely affect patent application confidential period time patent issue know competitor file patent application technology cover pende application invent technology subject patent application competitor file patent application receive patent obtain additional patent proprietary right block compete patent competitor file patent application cover technology participate interference proceeding litigation determine right patent litigation interference proceeding expensive ultimately successful patent relate pharmaceutical biopharmaceutical biotechnology product compound process cover exist compound product process likely file future provide complete adequate protection future litigation reexamination table content proceeding enforcement validity exist patent future patent invalidate patent substantially reduce protection addition pende patent application patent application file collaborative partner result issuance patent result patent provide adequate protection result able prevent party develop compound product develop develop addition certain country africa asia include china permit enforcement patent manufacturer able sell generic version product country approval process product fda determine product grant exclusivity period manufacturer application approval generic version product grant generic manufacturer wait challenge patent protect product grant exclusivity year prior end exclusivity period time time receive notice manufacturer indicate intend import chemical intermediate possibly use make product possible generic manufacturer consider attempt seek fda approval similar identical drug abbreviate new drug application application form typically manufacturer seek approval generic drug patent subject challenge need spend significant resource defend challenge able defend patent successfully rely unpatented trade secret improvement unpatente internal knowhow technological innovation particular great deal liposomal manufacturing expertise key component liposomal technology cover patent instead protect trade secret protect right mainly confidentiality agreement corporate partner employee consultant vendor agreement provide confidential information develop known individual course relationship keep confidential disclose party specify circumstance case employee agreement provide invention individual employ exclusive property certain party comply confidentiality agreement adequate remedy breach trade secret know independently discover competitor research development agreement invention discover certain case jointly own corporate partner case exclusive property difficult determine own particular invention dispute arise invention manufacture raw material antiviral product contract party manufacture antiviral product clinical commercial purpose include truvada viread atripla emtriva hepsera vistide tamiflu historically manufacture antiviral product commercialscale november acquire raylo chemicals inc raylo subsidiary germanybase specialty chemical company degussa ag raylos operation encompass custom manufacture active pharmaceutical ingredient advanced intermediate pharmaceutical biopharmaceutical industry result raylo acquisition ability produce tenofovir disoproxil fumarate emtricitabine edmonton alberta canada facility intend utilize site process research scaleup clinical development candidate manufacture active pharmaceutical ingredient investigational commercial product chemical development activity improve exist commercial manufacturing process use multiple thirdparty contract manufacturer manufacture tenofovir disoproxil fumarate active pharmaceutical ingredient viread component truvada atripla emtricitabine active pharmaceutical ingredient emtriva adefovir dipivoxil active pharmaceutical ingredient hepsera cidofovir active pharmaceutical ingredient vistide thirdparty contract manufacturer manufacture active pharmaceutical ingredient table content truvada viread atripla hepsera tablete perform thirdparty contract manufacturer manufacturer qualify approve supply product united states european union market emtriva capsulation complete thirdparty contract manufacturer use single thirdparty manufacturer supply vistide complete installation additional filling packaging capability facility san dimas california dublin ireland san dimas site receive regulatory approval united states approval european union expect half dublin site receive regulatory approval united states european union regulatory approval allow fill package drug product truvada viread atripla emtriva hepsera finish form roche party responsible manufacturing tamiflu agreement roche joint manufacturing committee compose representative roche opportunity review roche exist manufacturing capacity tamiflu global plan manufacture tamiflu future antiviral product continue consider develop additional manufacturing capability establish additional thirdparty supplier manufacture sufficient quantity product candidate undertake clinical trial manufacture sufficient quantity product approve commercial sale unable develop manufacturing capability internally contract large scale manufacturing party acceptable term future antiviral product ability conduct large scale clinical trial meet customer demand commercial product adversely affect believe technology use manufacture product proprietary antiviral product disclose necessary aspect technology contract manufacturer enable manufacture product agreement manufacturer intend restrict reveal technology certain manufacturer comply restriction addition manufacturer develop technology relate work perform need manufacture product require enter agreement manufacturer want use technology allow manufacturer use technology manufacturer refuse allow use technology demand term use technology acceptable ambisome manufacture ambisome commercial quantity facilities san dimas california medicines control agency united kingdom fda approve commercial production ambisome facility import ambisome european union manufacturing facility dublin ireland perform quality control testing final labeling packaging distribution european union use commercially available material equipment manufacture product currently obtain cholesterol use manufacture ambisome single approve supplier ambisome sell freezedrie product currently freezedry fill ambisome san dimas facility use party freezedry fill additional product need give current projection ambisome demand believe sufficient production capacity meet future demand option instal additional freezedrying capacity san dimas additional requirement necessary macugen manufacture macugen commercial quantity fda approve facilities san dimas manufacturing agreement osi use commercially available material equipment produce fill table content product currently osi provide raw material manufacture macugen include pegaptanib sodium active pharmaceutical ingredient macugen single approve supplier contract osi give osis current projection macugen demand believe sufficient production capacity meet future demand flolan gsk affiliate party exclusive right manufacture flolan distribution united states term distribution supply agreement gsk seasonal operation backlog worldwide product sale reflect significant degree seasonality royalty revenue represent total revenue tamiflu royalty comprise significant portion affect seasonality royalty revenue recognize roche sale tamiflu impact severity associate flu season product delivery response avian influenza pandemic threat operate market characterize short lead time absence significant backlog believe backlog information material business government regulation operation activity subject extensive regulation numerous government authority united states countries united states drug subject rigorous fda regulation federal food drug cosmetic act federal state statute regulation govern testing manufacture safety effectiveness labeling storage record keeping approval advertising promotion product result regulation product development product approval process expensive time consume fda approve drug sell united states general process approval follow preclinical testing test drug candidate human study drug laboratory experiment animal generate datum support drug potential benefit safety submit datum fda investigational new drug ind application seek approval test compound human clinical trial fda accept ind application study drug human clinical trial determine drug safe effective clinical trial involve separate phase overlap year expensive phase subject considerable regulation follow phase drug give small number healthy human control subject patient suffer indicate disease test safety dose tolerance pharmacokinetic metabolism distribution excretion phase drug give limited patient population determine effect drug treating disease well dose drug possible effect safety risk drug uncommon drug appear promise phase clinical trial fail rigorous phase clinical trial table content phase compound appear effective safe phase clinical trial phase clinical trial commence confirm result phase clinical trial longterm involve significantly large population conduct numerous site different geographic region carefully design provide reliable conclusive datum safety benefit drug uncommon drug appear promise phase clinical trial fail rigorous phase clinical trial fda approval process believe datum phase clinical trial show adequate level safety effectiveness file nda fda seek approval sell drug particular use fda review nda hold public hear independent advisory committee expert advisor ask additional question make recommendation drug committee make recommendation fda binding generally follow fda fda agree compound meet require level safety effectiveness particular use allow sell drug united states use unusual fda reject application believe drug safe effective believe datum submit reliable conclusive point process development drug stop number reason include safety concern lack treatment benefit certain clinical trial currently conduct conduct future complete successfully specified time period choose fda require delay suspend clinical trial time appear patient expose unacceptable health risk drug candidate appear sufficient treatment benefit fda require phase nonregistrational study explore scientific question characterize safety efficacy commercial use drug fda require provide additional data information improve manufacturing process procedure facility require extensive postmarketing test surveillance monitor safety benefit product candidate determine nda contain adequate evidence safety benefit drug addition fda approve drug limit use drug fda withdraw approval believe comply regulatory standard problem uncover occur approval addition obtain fda approval drug obtain fda approval manufacturing facility drug sell include company manufacture drug facility subject periodic inspection fda fda approve foreign establishment manufacture product sell united states facility subject periodic regulatory inspection manufacturing facility locate california include san dimas foster city facility license state california compliance local regulatory requirement manufacture facility locate canada include edmonton alberta facility obtain local license permit compliance local regulatory requirement drug treat lifethreatening disease condition adequately address exist drug development program design address unmet medical need designate fast track candidate fda eligible accelerate priority review drug treatment hiv designate use president emergency plan aid relief pepfar qualify expedite priority review viread truvada atripla receive accelerate approval priority review drug receive accelerated approval monitor postmarkete clinical trial order confirm safety benefit drug subject federal state local regulation workplace safety protection environment use hazardous material chemical viruse radioactive compound table content research development activity eliminate risk accidental contamination injury material misuse accident involve material lead significant litigation fine penalty drug subject extensive regulation outside united states european union centralize approval procedure authorize marketing product country european union include major country europe procedure approval country european union obtain approval country european union simplify application process mutual recognition procedure decentralize procedure rely principle mutual recognition receive regulatory approval european registration procedure pricing reimbursement approval require country price reimbursement successful commercialization depend availability governmental thirdparty payor reimbursement cost product government authority thirdparty payor increasingly challenge price medical product service business adversely affect increase global pricing pressure united states number legislative regulatory change healthcare system impact pricing product medicare prescription drug improvement modernization act medicare beneficiary able elect coverage prescription drug medicare entity provide coverage attempt negotiate price concession pharmaceutical manufacturer increase pressure low prescription drug price limit drug access prescription drug program begin january benefit patient transition medicaid medicare potentially detrimental impact long term new law business relate product united states clear impact depend specific decision level coverage provide therapeutic category product include term coverage provide extent preference give select product category medicare patient pay coinsurance influence product recommend physician select patient change medicare reimbursement negative effect revenue federal medicare proposal state medicaid drug payment change healthcare reform lower payment product addition extent private insurer blue cross blue shield manage care program follow medicaid coverage payment development adverse effect low medicare payment magnify private insurer adopt low payment schedule additionally state enact health care reform legislation federal state development possible europe success viread truvada emtriva hepsera ambisome tamiflu atripla marketing approval obtain european union depend largely obtain maintain government reimbursement european country patient use prescription drug reimburse government reimbursement available reimbursement policy adversely affect ability sell product profitable basis example europe international market government control price prescription pharmaceutical expect price prescription pharmaceutical decline life product volume increase new drug come market face significant price decrease product europe believe continue foreseeable future government struggle escalate health care spending result pricing practice difficult maintain historic level profitability achieve expect rate growth health care fraud abuse law subject federal state law pertain health care fraud abuse include antikickback law false claim law antikickback law illegal prescription drug manufacturer table content solicit offer receive pay remuneration exchange induce referral business include purchase prescription particular drug breadth statutory provision increase attention give law enforcement authority possible certain practice challenge antikickback similar law false claim law prohibit knowingly willingly present cause present payment thirdparty payor include medicare medicaid claim reimburse drug service false fraudulent claim item service provide claim claim medically unnecessary item service sale marketing activity subject scrutiny law violation fraud abuse law punishable criminal andor civil sanction include fine civil monetary penalty possibility exclusion federal health care program include medicare medicaid government allege convict violate law material adverse effect result operation november receive subpoena united states attorney office san francisco request document market medical education program truvada viread emtriva comply attorney subpoena intend cooperate relate government investigation compulsory license government develop country require grant compulsory license allow competitor manufacture sell version product reduce product sale example past certain office government brazil express concern affordability hiv product declare consider issue compulsory license permit manufacture patent product hiv infection include viread result discussion brazilian government reach agreement brazilian health ministry reduce price viread brazil approximately addition concern cost availability tamiflu fear grow potential avian flu pandemic generate international discussion potential compulsory licensing tamiflu patent example aware canadian government consider measure allow canadian manufacturer manufacture sell active ingredient tamiflu canada certain country furthermore roche issue voluntary license permit thirdparty manufacturing tamiflu example roche grant sublicense shanghai pharmaceutical group co ltd china sublicense indias hetero drug limited india certain develop country compulsory license issue permit generic manufacturing override tamiflu patent roche issue additional voluntary license permit thirdparty manufacturing tamiflu development reduce royalty receive roche sale tamiflu certain country permit enforcement patent manufacturer able sell generic version product country compulsory license generic version product significantly reduce sale adversely affect result operation particularly sale generic version product import territory exist commercial sale employee january approximately fulltime employee believe good relation employee environment seek comply applicable statutory administrative requirement concern environmental quality continue expenditure environmental compliance protection expenditure compliance environmental law expect material effect capital expenditure result operation competitive position table content information subject information requirement exchange act file periodic report proxy statement information sec report proxy statement information obtain visit public reference room sec f street ne washington dc call sec sec send electronic message sec publicinfosecgov send fax sec addition sec maintain website wwwsecgov contain report proxy information statement information issuer file electronically mail address headquarters lakeside drive foster city california telephone number location website wwwgileadcom link investors section website sec filings financial information section available follow filing soon reasonably practicable electronically file furnished sec annual report quarterly report form q current report form k amendment report file furnish pursuant section exchange act filing available free charge request item risk factor evaluate business carefully consider follow risk addition information annual report follow risk materially adversely affect business result operation financial condition note factor investor permit private security litigation reform act possible predict identify factor consider risk complete statement potential risk uncertainty face substantially revenue derive sale limited number product unable maintain continue increase sale hiv product result operation adversely affect currently dependent sale hiv product especially truvada viread support exist operation hiv product exclusively nucleoside class antiviral therapeutic treatment paradigm hiv change cause nucleosidebased therapeutic fall favor unable continue increase hiv product sale result operation likely suffer likely need scale operation include spend research development effort hiv product sale year end december billion approximately total revenue sale truvada viread account respectively total hiv product sale able continue growth rate sale hiv product reason state risk factor section particular follow reason hiv product long period time patient combination product additional study conduct new issue respect safety resistance interaction drug arise cause provide additional warning label narrow approve indication halt sale product reduce revenue product mature private insurer government reimburser reduce reimburse patient product increase pressure reduce price large market hiv product consist patient take hiv drug successful encourage physician change patient regimen include hiv product sale hiv product limit generic hiv product introduce major market ability maintain pricing affect table content fail commercialize new product expand indication exist product prospect future revenue stock price adversely affect introduce new product increase revenue exist product able increase maintain total revenue new product commercialization effort face risk outline section fail increase sale product bring new product market able increase revenue expand research development effort joint venture bms launch single tablet regimen truvada sustiva tradename atripla july united states physicians reluctant prescribe atripla fail advantage single tablet regimen antiretroviral result able increase revenue hiv product addition product sale atripla increase expense product sale component product overall total revenue increase launch atripla furthermore marketing authorization application submit bms merck october seek approval atripla european union grant timely basis face significant competition face significant competition business substantially great resource addition competitor product operate field compete long hiv product compete primarily product gsk market fixeddose combination product compete truvada atripla ambisome encounter significant competition new product produce merck pfizer addition aware report lipid formulation claim similarity ambisome available outside united states include anticipate entry formulation greece formulation reduce market demand ambisome furthermore manufacture lipid formulation amphotericin b complex formulation find unsafe sale ambisome negatively impact association hepsera encounter increase competition launch bmss baraclude entecavir launch novartisidenixs tyzeka telbivudine united states company substantially great resource significantly impede ability successful antiviral product ambisome addition develop aztreonam lysine inhalation treatment bacterial infection patient cf ambrisentan treatment pah approve aztreonam lysine compete tobi tobramycin inhalation market novartis ambrisentan compete directly actelion ltds tracleer bosentan indirectly pah product united therapeutics corporation pfizer significant safety issue arise market product product candidate future sale reduce adversely affect result operation datum support marketing approval product form basis safety warning product label obtain control clinical trial limit duration case limit postapproval use product include truvada viread atripla emtriva ambisome hepsera long period time patient take numerous medicine underlie health problem expect continue find new issue safety resistance drug interaction issue require provide additional warning contraindication label narrow approve indication reduce market acceptance product safety efficacy study viread emtriva dose separate product ongoing underway long period time safety efficacy study truvada viread emtriva underway conduct similar study atripla viread emtriva sustiva safety resistance interaction issue arise market product sale product limit halt regulatory authority addition follow acquisition myogen develop new product candidate darusentan ambrisentan different safety profile current market product new product table content candidate develop prove susceptible safety resistance drug interaction issue experience past safety issue arise product candidate clinical development program limit halt regulatory authority product candidate marketable product operation depend compliance complex fda comparable international regulation failure obtain broad approval timely basis achieve continued compliance delay halt commercialization product product develop approve marketing sale regulatory authority approve subject extensive regulation fda comparable regulatory agency country continue clinical trial truvada viread atripla emtriva ambisome hepsera currently approve additional use anticipate file marketing approval additional country additional product year product fail receive marketing approval timely basis addition market product manufacture sell product subject extensive continue regulation review discovery previously unknown problem market product problem manufacture promotional activity result restriction product include withdrawal product market fail comply applicable regulatory requirement subject penalty include fine suspension regulatory approval product recall seizure product criminal prosecution result clinical trial uncertain support continue development product pipeline adversely affect prospect future revenue growth require demonstrate safety effectiveness product develop intend use extensive preclinical study clinical trial result preclinical early clinical study accurately predict result later largescale clinical trial successfully complete largescale clinical trial result marketable product product development fail achieve primary endpoint clinical trial safety issue arise commercialization drug candidate delay halt addition clinical trial involve commercial product raise new safety issue exist product turn reduce revenue reliance thirdparty contract research organization conduct clinical trial unable directly control timing conduct expense quality clinical trial extensively outsource clinical trial activity usually perform small portion startup activity inhouse rely independent thirdparty contract research organization cro control perform clinical study include document preparation site identification screen preparation prestudy visit training program management bioanalytical analysis dispute disruption relationship cro clinical trial delay regulatory submission rely quality validity clinical work perform thirdparty cro cro process methodology result determine invalid inadequate clinical data result relate regulatory approval adversely impact february advise fda discover certain irregularity inspection bioanalytical analysis conduct organization thirdparty cro period review cro perform bioanalytical analysis study certain product know investigation involve impact clinical datum result relate regulatory approval table content able successfully integrate exist business business corus pharma inc raylo chemicals inc myogen inc integrate business exist business complex timeconsuming process recently corus raylo myogen operate independently business corporate culture location employee system result acquisition operate exist business business corus raylo myogen combine organization utilize common information communication system operating procedure financial control human resource practice include benefit train professional development program substantial difficulty cost delay involve integration company integration company asset time time acquire failure successfully integrate company asset company acquire material adverse effect business financial condition result operation remain effort completion coruss myogen research development project primarily consist clinical trial cost length success extremely difficult predict obtain necessary regulatory approval numerous risk uncertainty exist prevent completion development include ability enroll patient clinical trial possibility unfavorable result clinical trial risk fail obtain fda regulatory body approval feedback regulatory authority result clinical trial require modification delay later stage clinical trial additional trial perform certain aztreonam lysine cf purchase corus ambrisentan pah purchase myogen pende fda review approve united states country outside united states marketing approval significant limitation use future discussion regulatory agency determine datum need timeline review differ materially current projection acquire product candidate development successfully commercialize result strategic decision discontinue development product candidate example believe commercialization difficult relative opportunity pipeline program complete timely basis prospect future revenue growth adversely impact manufacturing problem delay product shipment regulatory approval adversely affect result operation depend party perform manufacturing activity effectively timely basis truvada viread atripla emtriva hepsera vistide manufacturing process pharmaceutical product highly regulate regulator shut manufacturing facility believe comply regulation manufacturer subject fda current good manufacturing practice extensive regulation govern manufacturing process stability testing record keep quality standard similar regulation effect country manufacture operation subject routine inspection regulatory agency additionally thirdparty manufacturer independent entity subject unique operational financial risk control extent risk materialize affect performance obligation adversely affect financial result depend thirdparty manufacturer manufacture truvada viread atripla available physician treatment program noprofit price develop country gilead access program rely party manufacture active pharmaceutical ingredient final drug product clinical commercial purpose addition roche party responsible manufacturing tamiflu thirdparty manufacturer fail perform require impair ability deliver product timely basis receive royalty cause table content delay clinical trial application regulatory approval event harm competitive position financial result able manufacture ambisome macugen meet market need event business interruption san dimas facility manufacture ambisome fill finish macugen facilities san dimas california formulation manufacturing facility united states event natural disaster include earthquake equipment failure strike difficulty unable replace manufacturing capacity timely manner unable manufacture ambisome macugen meet market need ability successfully manufacture commercialize aztreonam lysine approve depend ability continue manufacture multiproduct facility aztreonam lysine monolactam gramnegative antibiotic currently plan manufacture party multiproduct manufacturing facility historically fda permit manufacture monolactams multi product manufacturing facility assurance fda continue allow practice currently singleproduct facility dedicate manufacture aztreonam lysine engage contract manufacturer singleproduct facility aztreonam lysine fda prohibit manufacture monolactam antibiotic like aztreonam lysine multiproduct manufacturing facility future able procure singleproduct manufacturing facility timely manner adversely affect commercial supply aztreonam lysine anticipate financial result attributable product approve able obtain material supply necessary manufacture sell product limit ability generate revenue material utilize operation facility example depend single supplier high quality cholesterol manufacture ambisome supplier key component material name nda file fda product significant delay occur qualification new supplier require delivery material supplier interrupt reason unable ship truvada viread atripla emtriva hepsera ambisome vistide supply product development clinical trial addition aztreonam lysine inhalation develop administer lung patient device single supplier currently work supplier prepare commercial launch aztreonam lysine inhalation regulatory approval obtain sufficient quantity device available time commercial launch follow launch encounter problem relationship supplier commercial launch aztreonam lysine inhalation delay anticipate contribution aztreonam lysine financial result adversely effect table content depend relationship company sale marketing performance revenue failure maintain relationship poor performance company dispute company negatively impact business rely number significant collaborative relationship major pharmaceutical company sale marketing performance certain territory include collaboration astella create merger yamanouchi pharmaceutical co ltd fujisawa pharmaceutical co ltd sumitomo ambisome gsk hepsera roche tamiflu pfizer vistide osi pfizer macugen japan tobacco viread truvada emtriva joint venture bms atripla country rely international distributor sale truvada viread emtriva ambisome hepsera relationship involve clinical development product partner reliance collaborative relationship pose number risk include risk able control resource corporate partner devote program product dispute arise respect ownership right technology develop corporate partner disagreement corporate partner cause delay termination research development commercialization product candidate result litigation arbitration contract corporate partner fail provide significant protection fail effectively enforce partner fails perform corporate partner considerable discretion elect pursue development additional product pursue alternative technology product collaboration competitor corporate partner marketing right choose pursue compete technology devote few resource marketing product product development distributor corporate partner unable pay give risk great deal uncertainty success current future collaborative effort effort fail product development commercialization new product delay revenue exist product decline april licensing agreement gsk give gsk right control clinical regulatory development commercialization hepsera territories asia africa latin america include major market hepsera china japan taiwan republic korea success hepsera territory depend entirely effort gsk regard gsk promote epivirhbvzeffix product compete hepsera consequently gsk marketing strategy hepsera influence promotion epivirhbvzeffix receive royalty gsk equal percentage gsk net sale hepsera net sale gsk epivirhbvzeffix gsk fail devote sufficient resource succeed develop commercialize hepsera territory potential revenue sale hepsera territory substantially reduce expense associate clinical trial sale fluctuation result inventory level hold wholesaler cause earning fluctuate adversely affect stock price clinical trial require regulatory approval product clinical trial require conduct approval expensive difficult accurately predict control timing expense quarter quarter uneven unexpected spending program cause operating result fluctuate quarter quarter table content estimate future demand product consider shelf life inventory regularly review realizability inventory actual demand estimate demand require record inventory writedown adverse impact result operation example result review inventory realizability fourth quarter record writedown portion gilead access program inventory additional write down inventory gilead access program necessary demand hiv product access program country sufficient consume exist inventory year end december approximately product sale united states wholesaler amerisourcebergen corp cardinal health inc mckesson corp inventory level hold wholesaler cause operating result fluctuate unexpectedly sale wholesaler match end user demand wholesaler enter inventory management agreement completely effective match inventory level end user demand estimate determine end user demand nonretail sector united states include government institution correctional facility large health maintenance organization currently contribute approximately hiv business tend consistent term buy pattern result quarter quarter fluctuation necessarily mirror growth pattern see retail prescription datum unpredictable variability roche tamiflu sale strong relationship revenue global pandemic planning cause royalty revenue fluctuate quarter quarter success depend significant degree ability protect patent intellectual property right domestically internationally number patent patent application right patent relate compound product certain issue patent enforceable provide adequate protection pende patent application result issue patent competitor file patent application receive patent obtain additional patent proprietary right block compete patent patent application confidential period time patent issue result know competitor file patent application technology cover pende application invent technology subject patent application competitor file patent application cover technology participate interference proceeding litigation determine right patent litigation interference proceeding expensive ultimately successful approval process product fda determine product grant exclusivity period manufacturer application approval product grant generic manufacturer wait challenge patent protect product year prior end exclusivity period time time receive notice manufacturer indicate intend import chemical intermediate possibly use make product possible generic manufacturer consider attempt seek fda approval similar identical drug abbreviate new drug application application form typically manufacturer seek approval generic drug patent subject challenge need spend significant resource defend challenge able defend patent successfully success depend large ability operate infringe patent proprietary right party infringe patent prevent commercialize product require obtain license party able obtain alternative technology require license reasonable term fail obtain license alternative technology unable develop commercialize product table content addition use significant proprietary technology rely unpatented trade secret proprietary knowhow protect certain aspect production technology trade secret know independently discover competitor approximately half product sale occur outside united states currency fluctuation cause earning fluctuate adversely affect stock price significant percentage product sale denominate foreign currency primarily euro increase value dollar foreign currency past reduce future reduce dollar equivalent sale negatively impact financial condition result operation use foreign currency forward contract hedge percentage forecast international sale primarily denominate euro currency hedge portion account receivable balance denominate foreign currency reduce eliminate exposure currency fluctuation date sale record date cash collect hedge program hedge portion total exposure significant foreign exchange rate fluctuation short period time adversely affect result operation face credit risk european customer adversely affect result operation european product sale government own support customer greece italy portugal spain subject significant payment delay government funding reimbursement practice account receivable government own support customer country total million december historically receivables tend accumulate period time settle large lump sum payment government funding available significant change occur reimbursement practice european government government funding unavailable able collect amount customer result operation adversely affect product revenue reduce import country product available low price price product base local market economic competition differ country country sale country relatively high price reduce product import country low price market case pharmaceutical product sell steeply discount price develop world reexporte european country resold high price happen product particularly truvada viread agree available noprofit price country participate gilead access program atripla merck distribute low cost hivinfecte patient develop country august agreement revenue adversely affect addition grant nonexclusive voluntary license manufacture tenofovir disoproxil fumarate generic manufacturer india local indian market manufacturer export product develop world country include gilead access program generic version viread license reexporte united states europe market outside india develop world country participate gilead access program revenue adversely affect addition european union required permit crossborder sale allow buyer country governmentapprove price product relatively high purchase product legally country sell low price purchase product country sale price relatively low resale country sale price relatively high adversely impact gross margin cause sale fluctuate quarter quarter fourth quarter see increase instance crossborder sale europe additionally consumer able purchase product include hiv product internet pharmacy country substantial discount crossborder sale adversely affect revenue table content country require grant compulsory license product face generic competition product number develop country government official group suggest pharmaceutical company drug hiv infection available low cost alternatively government country require grant compulsory license allow competitor manufacture sell version product reduce product sale example past certain office government brazil express concern affordability hiv product declare consider issue compulsory license permit manufacture patent product hiv infection include viread result discussion brazilian government reach agreement brazilian health ministry reduce price viread brazil approximately addition concern cost availability tamiflu fear grow potential avian flu pandemic generate international discussion potential compulsory licensing tamiflu patent example aware canadian government consider measure allow canadian manufacturer manufacture sell active ingredient tamiflu canada certain country furthermore roche issue voluntary license permit thirdparty manufacturing tamiflu example roche grant sublicense shanghai pharmaceutical group co ltd china sublicense indias hetero drug limited india certain develop country compulsory license issue permit generic manufacturing override tamiflu patent roche issue additional voluntary license permit thirdparty manufacturing tamiflu development reduce royalty receive roche sale tamiflu certain country permit enforcement patent manufacturer able sell generic version product country compulsory license sale generic version product significantly reduce sale adversely affect result operation particularly generic version product import territory exist commercial sale exist product subject reimbursement government agency party pharmaceutical pricing reimbursement pressure reduce profitability successful commercialization product depend availability governmental thirdparty payor reimbursement cost product relate treatment government health administration authority private health insurer organization generally provide reimbursement government authority thirdparty payor increasingly challenge price medical product service particularly innovative new product therapy result low average sale price example majority sale ambisome vistide majority sale truvada viread atripla hepsera subject reimbursement government agency result significant discount list price rebate obligation business adversely affect increase international pricing pressure pressure arise rule practice manage care group judicial decision governmental law regulation relate medicare medicaid health care reform pharmaceutical reimbursement policy price general europe success truvada viread emtriva hepsera ambisome tamiflu atripla approve european union depend largely obtain maintain government reimbursement european country patient unlikely use prescription drug reimburse government addition negotiate price governmental authority delay commercialization month expect success product development particularly europe depend ability obtain reimbursement reimbursement available reimbursement policy adversely affect ability sell product profitable basis example europe international market government control price prescription pharmaceutical expect price prescription pharmaceutical decline life product volume increase new drug come market face significant price decrease product europe believe continue foreseeable future government struggle escalate health care table content spending result pricing practice difficult maintain historic level profitability achieve expect rate growth result operation adversely affect current future health care reform legislative regulatory change government prescription drug procurement reimbursement program occur relatively frequently united states foreign jurisdiction recently significant change federal medicare system united states impact pricing product medicare prescription drug improvement modernization act medicare beneficiary able elect coverage prescription drug medicare entity provide coverage attempt negotiate price concession pharmaceutical manufacturer increase pressure low prescription drug price limit drug access prescription drug program begin january benefit initially patient transition medicaid medicare long term impact new law business clear impact depend specific decision level coverage provide therapeutic category product include term coverage provide extent preference give select product category medicare patient pay co insurance influence product recommend physician select patient change medicare reimbursement negative effect revenue federal medicare proposal state medicaid drug payment change healthcare reform lower payment product result operation materially adversely affect reimbursement change emerge medicare prescription drug coverage legislation addition extent private insurer blue cross blue shield manage care program follow medicaid coverage payment development adverse effect low medicare payment magnify private insurer adopt low payment schedule additionally state enact health care reform legislation federal state development possible able obtain effective patent protect technology use competitor patent company require stop pay use require technology success depend significant degree ability obtain patent license patent right preserve trade secret operate infringe proprietary right number foreign patent patent application right patent relate compound product technology risk issue patent enforceable provide adequate protection pende patent application result issue patent patent application confidential period time patent issue result know competitor file patent application technology cover pende application invent technology subject patent application competitor file patent application receive patent obtain additional patent proprietary right block compete patent patent cover active ingredient ambisome addition patent filing china certain asian country cover form adefovir dipivoxil active ingredient hepsera asia major market therapie hbv indication hepsera develop flolan patent market exclusivity protection expired result generic pharmaceutical company launch attempt launch generic version flolan united states obtain patent certain product year marketing approval obtain product patent limited life begin run prior commercial sale relate table content product commercial value patent limit able apply patent term extension addition certain country africa asia include china permit enforcement patent manufacturer able sell generic version product country competitor file patent application cover technology participate interference proceeding litigation determine right patent litigation interference proceeding expensive ultimately successful approval process product fda determine product grant exclusivity period manufacturer application approval generic version product grant generic manufacturer wait challenge patent protect product grant exclusivity year prior end exclusivity period time time receive notice manufacturer indicate intend import chemical intermediate possibly use make product possible generic manufacturer consider attempt seek fda approval similar identical drug abbreviate nda application form typically manufacturer seek approval generic drug patent subject challenge need spend significant resource defend challenge able defend patent successfully success depend large ability operate infringe patent proprietary right party infringe patent prevent commercialize product require obtain license party able obtain alternative technology require license reasonable term fail obtain license alternative technology unable develop commercialize product addition use significant proprietary technology rely unpatented trade secret proprietary knowhow protect certain aspect production technology trade secret know independently discover competitor face significant liability result product cover insurance successful claim materially reduce earning testing manufacturing marketing use commercial product product development involve substantial risk product liability claim claim directly consumer healthcare provider pharmaceutical company product liability insurance cover successful product liability claim require pay amount provide insurance impair financial condition ability clinically test market product assumption determine selfinsurance level wrong materially impact business continually evaluate level selfinsurance base historical claim experience demographic factor severity factor actuarial assumption future occurrence claim differ assumption historical trend result operation business cash flow financial condition materially impact claim expense expensive litigation government investigation reduce earning name defendant lawsuit use average wholesale price reimbursement rate medicaid addition plaintiff appeal dismissal class action lawsuit bring allege violation federal security law november receive subpoena table content united states attorney office san francisco request document market medical education program truvada viread emtriva comply attorney subpoena intend cooperate relate government investigation outcome lawsuit lawsuit bring investigation investigation bring inherently uncertain adverse development outcome result significant monetary damage penalty injunctive relief significantly reduce earning cash flow change effective income tax rate reduce earning factor favorable unfavorable effect income tax rate factor include limited interpretation exist tax law adoption statement financial accounting standard sfas revise sharebased payment sfas r relate accounting stock option sharebase payment change tax law rate merger acquisition future level research development rd spending change accounting standard future level capital expenditure change mix earning tax jurisdiction operate change overall level pretax earning finalization federal state income tax audits impact income tax provision result abovementione factor significant negative impact net income loss change account stock option significantly reduce continue significantly reduce earning subject sfas r require record additional compensation expense relate stock option sharebase payment january standard continue significant negative impact report result operation compare result report prior prior accounting standard stock option sharebase payment fail attract retain highly qualified personnel unable successfully develop new product candidate conduct clinical trial commercialize product candidate future success depend large continue ability attract retain highly qualified scientific technical management personnel personnel expertise clinical testing governmental regulation commercialization face competition personnel company university public private research institution government entity organization competition qualified personnel biopharmaceutical field intense limited pool qualified potential employee recruit able attract retain quality personnel acceptable term unsuccessful recruitment retention effort business harm item b unresolved staff comment applicable item property corporate headquarters include principal executive office commercial administrative research development facility locate foster city california location building lease facility san dimas california house manufacturing warehousing research development activity addition lease facility durham north carolina westminster colorado seattle washington house administrative research development activity table content european headquarter include commercial medical administrative facility locate london area united kingdom lease facility dublin area ireland house manufacturing distribution activity addition lease facility house commercial medical administrative activity austria australia canada france germany greece italy portugal spain turkey united kingdom manufacturing facility edmonton alberta canada use conduct process research scaleup clinical development candidate manufacture active pharmaceutical ingredient investigational commercial product chemical development activity improve exist commercial manufacturing process believe exist property include own lease site good condition suitable conduct business believe capital resource sufficient purchase lease construct additional facility require meet longterm growth need item legal proceeding information pertain legal proceeding find head legal proceeding item note commitment contingency consolidate financial statement page annual report incorporate reference item submission matter vote security holder matter submit vote security holder quarter end december table content ii item market registrant common equity relate stockholder matter issuer purchase equity security common stock trade nasdaq global select market symbol gild follow table set forth period indicate high low intraday sale price share common stock nasdaq global select market price represent quotation dealer adjustment retail markup markdown commission represent price actual transaction high low quarter second quarter quarter fourth quarter quarter second quarter quarter fourth quarter february share common stock outstanding hold approximately stockholder record pay cash dividend common stock inception currently expect retain earning use operation expansion business anticipate pay cash dividend near future table content performance graph follow graph compare total stockholder return past year index nasdaq crsp total return index nasdaq global select market company label nasdaqus nasdaq pharmaceutical index label nasdaqpharmaceutical total return common stock index assume reinvestment dividend cash dividend declare common stock base return component company weight accord capitalization end monthly period nasdaqus track aggregate price performance equity security company trade nasdaq global select market nasdaqpharmaceutical track aggregate price performance equity security pharmaceutical company trade nasdaq global select market common stock trade nasdaq global select market component nasdaqus nasdaqpharmaceutical index stockholder return show graph necessarily indicative future performance endorse prediction future stockholder return comparison cumulative total return investment past year section soliciting material deem file sec incorporate reference filing securities act exchange act date hereof irrespective general incorporation language filing show cumulative return investment assume investment common stock nasdaqus nasdaqpharmaceutical indice december table content item select financial datum gilead sciences inc select consolidated financial datum thousand share datum year end december consolidated statement operation datum total revenue purchase inprocess research development note total cost expense note income loss operation gain warrant note loss sale osi common stock note provision benefit income taxis note net income loss net income loss sharebasic note share share calculationbasic note net income loss sharedilute note share share calculationdilute note december consolidated balance sheet datum cash cash equivalent marketable security work capital total asset longterm obligation note convertible debt note retain earning accumulate deficit total stockholder equity note note complete acquisition myogen aggregate purchase price billion billion allocate purchase inprocess research development million allocate defer tax asset primarily related federal net operating loss tax credit carryforward certain state amortization million allocate goodwill million allocate net tangible asset acquire net asset corus million million allocate purchase inprocess research development million allocate net defer tax asset primarily related federal net table content gilead sciences inc select consolidated financial datacontinued operating loss tax credit carryforward certain state amortization million allocate net tangible asset million allocate assemble workforce recognize million royalty revenue relate resolution dispute roche record tax provision benefit million relate repatriation qualified foreign earning american job creation act ajca record gain million relate warrant purchase capital stock eyetech pharmaceuticals inc predecessor osi complete initial public offering complete acquisition net asset triangle aggregate purchase price million approximately million purchase price allocate purchase inprocess research development record income tax benefit million relate reduction valuation allowance certain net defer tax asset sell share common stock osi recognize loss sale marketable security million share partial consideration sale oncology asset note adopt sfas r modify prospective basis begin january note consolidated financial statement note march september implement twoforone stock split form stock dividend share share amount period present restate reflect stock split note issue billion principal convertible senior note private placement enter uncollateralized million term loan facilitate cash dividend distribution repatriation qualified foreign earning provision ajca note cash dividend declare pay common stock table content item management discussion analysis financial condition result operation follow management discussion analysis mda intend help reader understand result operation financial condition mda provide supplement read conjunction audit consolidated financial statement accompany note financial statement disclosure include annual report include disclosure item risk factor consolidate financial statement prepare accordance generally accept accounting principle present dollar executive summary experience successful year achievement significant financial operating milestone drive continued growth sale hiv product truvada viread atripla emtriva total product sale reach billion increase couple significant increase royalty revenue year total revenue increase billion sale hiv product billion represent increase hiv product sale primarily drive continued growth truvada especially europe truvada product sale comprise half total hiv product sale launch atripla single tablet regimen truvada bristol myers squibb company bms sustiva efavirenz united states july successful uptake half year contribute high hiv product sale building momentum establish joint venture bms september establish threeway joint venture bms merck co inc merck hold european marketing authorization atripla joint venture file marketing authorization european medicine agency october centralize licensing procedure marketing authorization application finalize approve joint venture hold marketing authorization member states european union discussion company agreement manufacture commercialization distribution atripla european union ongoing sale increase generate strong performance truvada atripla partially offset decrease sale viread primarily patient switch vireadcontaine regimen contain truvada andor atripla country truvada andor atripla available despite face continue strong competitive force worldwide sale ambisome increase slightly percent compare previously anticipate availability new treatment option patient live hepatitis b infection help hbv market expand hepsera product sale increase drive primarily sale volume growth europe addition growth product sale royalty revenue increase significantly year million royalty revenue recognize million come royalty sale tamiflu f hoffmannla roche ltd hoffmannla roche inc roche tamiflu royalty increase strong sale tamiflu roche include sale tamiflu relate pandemic planning initiative worldwide elimination contractual cost good adjustment implement january adopt provision statement financial accounting standard sfas revise sharebased payment sfas r begin expense fair value stockbase award result stockbase compensation expense significant component increase operating cost expense year end december compare prior year discussion adoption sfas r include critical accounting policy estimate judgment year focus create solid foundation longterm growth highlight strong performance antiinfective hiv hbv antifungal strategy building foundation continue opportunity acquire inlicense partner innovative table content technology drug candidate develop technology alongside inhouse initiative implement strategy complete significant acquisition acquire additional innovative technology drug candidate august complete acquisition corus pharma inc corus privatelyheld development stage biopharmaceutical company base seattle washington focus development commercialization novel drug respiratory infectious disease aggregate purchase price million corus product candidate latestage clinical development aztreonam lysine inhalation treatment patient cystic fibrosis pulmonary infection pseudomona aeruginosa november complete acquisition outstanding share common stock myogen inc myogen publiclyheld biopharmaceutical company base westminster colorado focus discovery development commercialization small molecule therapeutic treatment cardiovascular disorder aggregate purchase price billion myogen product candidate latestage clinical development ambrisentan treatment patient pulmonary arterial hypertension darusentan treatment patient resistant hypertension believe acquisition corus myogen provide opportunity expand respiratory cardiopulmonary therapeutic area clinic considerable progress compound drug candidate inlicense collaboration partner hiv quarter dose patient phase clinical study novel integrase inhibitor hiv gs license japan tobacco inc japan tobacco february announce completion phase clinical trial announce clinical study meet primary endpoint noninferiority viral load reduction hiv positive patient hepatitis area complete enrollment patient pivotal phase clinical study tenofovir disoproxil fumarate chronic hepatitis b second quarter collaboration partner achillion pharmaceuticals inc begin dose hcvinfecte patient phase viral dynamic clinical study gs small molecule inhibitor hcv fourth quarter february base preliminary datum study company decide discontinue development gs hcv infection file investigational new drug application fda gs nonnucleoside hcv polymerase inhibitor potential treatment hepatitis c begin dose infect patient phase clinical study gs fourth quarter anticipate datum gs program second quarter continue explore new opportunity significant unmet medical need longterm growth strategy primary focus develop current pipeline include drug product candidate corus myogen acquisition success commercially research development perspective product strong global organization infrastructure build past year continue invest infrastructure facilitate continue strong growth relocate european commercial medical administrative headquarters france united kingdom unite function regulatory safety information technology group headquarter united kingdom undertake strategic realignment international commercial organization well build manage expand presence new exist market year began assess address way distribute product market serve enhance manufacturing capability growth demand product increase need timely adequate procurement clinical material focus continuously look way manufacture efficiently effectively complete acquisition raylo chemicals inc raylo whollyowne subsidiary germanybase specialty chemical company degussa ag november aggregate purchase price million locate edmonton alberta canada raylos operations encompass custom manufacture active pharmaceutical ingredient api advanced intermediate pharmaceutical biopharmaceutical industry intend utilize edmonton site process research scaleup clinical development candidate manufacture api investigational commercial product chemical development activity improve exist commercial manufacturing process table content cost fund corporate development opportunity build infrastructure meeting daily operating need continue area management focus generate operating cash flow billion continued explore way access cash order fund corporate initiative april take advantage favorable market corporate condition issue billion principal convertible senior note concurrently repurchase million common stock stock repurchase program purchase convertible note hedge cost million sell warrant proceed million transaction operate cash flow help fund significant cash outlay require year myogen corus raylo acquisition million payment principal term loan result december cash cash equivalent marketable security balance billion currently anticipate current cash cash equivalent marketable security revolve credit facility adequate satisfy capital need foreseeable future focus continue build infrastructure advance drug candidate clinic accomplish operational goal promote product safety efficacy datum drive high patient adoption intend continue build strong working relationship corporate partner roche respect tamiflu bms merck respect atripla glaxosmithkline respect hepsera number acquisition significant energy invest ensure successfully integrate people process system edmonton seattle westminster site expend significant resource prepare launch ambrisentan united states file new drug application nda aztreonam lysine inhalation united states finally continue strengthen global infrastructure well support grow employee customer base well facilitate expand manufacture research development commercial activity ensure activity undertake employee continue execute framework high integrity critical accounting policy estimate judgment discussion analysis financial condition result operation base consolidated financial statement prepare accordance generally accept accounting principle preparation financial statement require estimate judgment affect report amount asset liability revenue expense related disclosure ongoing basis evaluate estimate include related revenue recognition allowance doubtful account inventory prepay royalty clinical trial accrual tax provision stockbase compensation base estimate historical experience marketspecific assumption believe reasonable circumstance result form basis make judgment carry value asset liability readily apparent source actual result differ significantly estimate believe follow critical accounting policy reflect significant judgment estimate preparation consolidated financial statement revenue recognition product sale recognize revenue product sale persuasive evidence arrangement exist delivery customer occur price fix determinable collectibility reasonably assure record estimate reduction revenue government rebate medicaid reimbursement customer incentive cash discount prompt payment distributor fee expect return expire product estimate deduct gross product sale time revenue recognize reduction gross product sale government rebate significantly impact report net product sale base certain estimate require complex significant management judgment table content government rebate estimate amount payable governmentmanage medicaid program certain qualify federal state government program reimbursement portion retail price prescription fill cover program government rebate invoice directly record accrue liability consolidate balance sheet qualified program purchase product wholesaler low contractual government price wholesaler charge difference acquisition cost low price record allowance account receivable estimate sale allowance base contractual term historical utilization rate new information change program regulation guideline impact actual rebate expectation future utilization rate program channel inventory datum obtain major wholesaler accordance inventory management agreement million million million respectively represent total gross product sale respectively deduct gross product sale government rebate base current information available actual government rebate claim period vary estimate record period december accrue government rebate million million respectively accrue liability allowance million million respectively record account receivable follow table summarize aggregate activity accrue government rebate allowance accrue liability account balance deduct balance begin charge end year expense accrual year year end december government rebate allowance accrue liability activity relate sale activity relate sale prior total year end december government rebate allowance accrue liability activity relate sale activity relate sale prior total contract revenue contract revenue research development rd record performance occur earning process complete base performance requirement contract nonrefundable contract fee performance obligation exist continue involvement recognize payment receive collection reasonably assure revenue nonrefundable upfront license fee milestone payment continue involvement development collaboration obligation supply product recognize performance occur obligation complete accordance specific term obligation type arrangement revenue recognize obligation fulfil ratably development manufacturing period revenue associate substantive atrisk milestone recognize base achievement milestone define respective agreement advance payment receive excess amount earn classified deferred revenue table content allowance doubtful account maintain allowance doubtful account estimate loss result inability customer require payment allowance base analysis factor include limited contractual payment term historical payment pattern customer individual customer circumstance analysis day sale outstanding customer geographic region review local economic environment potential impact government funding reimbursement practice financial condition customer economic environment operate deteriorate result inability payment additional allowance require allowance doubtful account balance percentage total account receivable materially change december december believe allowance doubtful account adequate cover anticipate loss current condition significant deterioration factor especially respect government funding reimbursement practice european market materially change expectation result increase allowance doubtful account inventory record writedown value inventory base review bad batch experience manufacturing process quality control review inventory generally record inventory writedown relate estimate obsolescence risk competition primarily shelf life product long current assumption future production inventory level demand competition change actual market condition favorable project management additional inventory writedown require negatively impact product gross margin result operation prepay royalty capitalize royalty prepay cost specifically related emtricitabine royalty pay emory university emory hiv indication base present value future royalty obligation expect pay emory assume certain expect future level product sale incorporate emtricitabine technology present value future royalty obligation derive weighted average cost capital review quarterly expect future sale level product indicator require writedown net recoverable value asset change estimate life prepay royalty potential indicator impairment include launch significant product competitor significant deviation recognize product sale compare forecast product safety issue recall amortize prepay royalty base effective royalty rate derive forecast hiv product sale incorporate emtricitabine product sale forecast prepare annually determine good estimate future activity consider factor historical expect future patient usage uptake product introduction complimentary combination therapie product future product launch plan previously unanticipate significant change occur sale forecast include introduction compete product competitor hiv market emtricitabine prospectively update royalty rate amortize prepay royalty increase future royalty expense december prepay royalty asset relate emtricitabine royalty pay emory million amortization expense relate prepay royalty asset million million year end december respectively clinical trial accrual record accrual estimate clinical study cost clinical study perform thirdparty contract research organization cro cost significant component rd expense incur cro cost million million million respectively table content accrue cost clinical study perform cro straightline basis service period specify contract adjust estimate require base ongoing review level effort cost actually incur cro validate accrual quarterly vendor perform detailed review activity relate significant contract base result validation process assess appropriateness accrual adjustment deem necessary ensure expense reflect actual effort incur cro generally significant portion total clinical trial cost associate start activity trial patient enrollment extensively outsource clinical trial activity usually perform small portion startup activity house result cro typically perform total startup activity trial include document preparation site identification screen preparation prestudy visit training program management budget basis cost typically total contract value actual basis percentage range significantly wider contract expand reduced scope compare original budget startup cost particular trial change significantly startup cost usually occur month contract execute milestone event drive nature remain activity relate cost patient monitor administration generally occur ratably life individual contract study contract negotiate fix unit price vary length month single dose phase study year complex phase study average length contract upper end range order provide longterm safety efficacy datum support commercial launch truvada viread atripla emtriva hepsera material cro contract terminable write notice gilead generally liable actual effort expend cro point time contract regardless payment status amount pay advance service perform refunded contract terminate december difference actual estimate activity level particular study significant require material adjustment management receive complete accurate information vendor underestimate activity level associate study give point time record additional potentially significant rd expense future period tax provision estimate income tax provision include defer tax asset liability base significant management judgment evaluate realization portion defer tax asset quarterly basis record valuation allowance reduce defer tax asset amount likely realize consider future taxable income ongoing tax planning strategy historical financial performance assess need valuation allowance purchase myogen fourth quarter determine likely certain acquire defer tax asset relate state net operating loss carryforward realize establish valuation allowance approximately million expect realize defer tax asset previously record valuation allowance reduce valuation allowance period determination adjustment fourth quarter determine likely certain defer tax asset realized release related valuation allowance result income tax benefit approximately million future effective income tax rate affect factor change tax law regulation rate change interpretation exist law regulation impact accounting stockbase compensation change international organization change overall level income tax table content income tax return routinely audit state foreign tax authority differ interpretation tax law regulation result significant dispute arise tax authority involve issue time deduction allocation income tax jurisdiction periodically evaluate exposure associate tax filing position believe position comply applicable law record liability base sfas accounting contingency believe item currently pende material adverse effect consolidated financial statement include annual report adverse resolution item quarterly reporting period cover consolidated financial statement material impact result operation period stockbase compensation december financial accounting standard board fasb issue sfas r require sharebase payment employee director include grant stock option recognize statement operation base fair value sfas r supersede accounting principle board opinion accounting stock issue employee apb amend sfas statement cash flow january adopt sfas r modify prospective method adoption permit sfas r require compensation expense record nonveste stock option stockbase award begin quarter adoption accordance modify prospective method prior period amount restate reflect provision sfas r prior adoption sfas r accordance provision sfas elect follow apb fasb interpretation account certain transaction involve stock compensationan interpretation apb opinion accounting employee stockbase plan apb exercise price employee director stock option equal great fair value underlie stock date grant compensation expense recognize require sfas pro forma impact expense fair value stock option employee stock purchase plan disclose note consolidated financial statement connection adoption sfas r refined valuation assumption methodology derive assumption elect continue blackschole option valuation model fair value stock option grant prior adoption sfas r calculate multiple option approach fair value stock option grant begin january calculate single option approach concurrent adoption sfas r determined blend historical volatility imply volatility trade option stock well measure market condition expect volatility previously historical stock price volatility reliable source volatility datum estimate weightedaverage expect life stock option base historical cancellation exercise datum relate stock option contractual term vest term award record stockbase compensation expense grade vest expense attribution approach nonveste stock option grant prior adoption sfas r consistent expense attribution approach historical sfas disclosure straight line expense attribution approach stock option grant adoption sfas r currently believe straightline expense attribution approach well reflect level service provide vest period award stockbase compensation expense relate stock option recognize net estimate forfeiture estimate forfeiture base historical experience result adoption sfas r recognize benefit stockbase compensation additional paidincapital apic incremental tax benefit realize tax attribute currently available utilize addition elect account indirect benefit stockbase compensation research tax credit extraterritorial income deduction consolidate statement operation apic table content year end december recognize stockbased compensation expense million operating expense capitalize million inventory december unrecognize stockbase compensation million relate nonveste stock option expect expense estimate weightedaverage period year senior management discuss development selection disclosure critical accounting policy audit committee board director audit committee review disclosure present relate result operation total revenue total revenue billion billion billion include total revenue product sale royalty revenue contract revenue product sale product sale year consist follow thousand change change hiv product truvada viread atripla emtriva total hiv product sale hepsera ambisome total product sale total product sale increase compare compare case primarily increase volume sale hiv product significant percentage product sale continue denominate foreign currency use forward contract hedge percentage forecast international sale primarily denominate euro reduce eliminate fluctuation sale change foreign currency exchange rate hiv product viread emtriva truvada atripla approve sale united states october july august july respectively viread emtriva truvada approve sale european union february october february respectively currently seek approval atripla sale european union hiv product sale increase compare compare primarily drive product volume growth experience steady prescription gain hiv product portfolio average selling price hiv product increase compare primarily drive higher overall selling price hiv product transition patient united states coverage medicaid medicare reduce medicaid claim result table content transition estimate assume patient dually eligible medicaid fact transition medicare benefit net product sale result reduction medicaid claim approximately million truvada truvada sale increase compare primarily drive strong sale volume growth major geographic region truvada sale account total hiv product sale respectively reflect strong position nrti backbone choice united states rapid significant uptake key european territory truvada sale increase united states year truvada sale primarily patient new therapy secondarily patient switch regimen include contain viread andor emtriva viread viread sale decrease compare primarily patient switch vireadcontaine regimen contain truvada country truvada available partially offset sale volume increase latin america viread sale relatively consistent sale level result continue strong performance viread despite offset impact patient switch vireadcontaine regimen contain truvada country truvada available atripla atripla sale million consolidate atripla product sale primary beneficiary joint venture bms sale include approximately million relate sustiva atripla approve sale united states july account hiv product sale launch december emtriva emtriva sale decrease compare compare decrease year primarily drive impact patient switch emtrivacontaine regimen contain truvada andor atripla country product available hepsera hepsera sale increase compare compare primarily drive sale volume growth europe united states hepsera sale volume increase respect sale hepsera glaxosmithkline inc gsk sell hepsera gsk manufacturing cost connection gsk distribution activity asia royalty earn sale hepsera gsk record royalty revenue ambisome sale ambisome increase percent compare increase percent compare increase comparative period primarily increase sale united states ambisome product sale united states relate solely sale ambisome astellas pharma inc astellas record manufacturing cost royalty earn sale ambisome astella discuss royalty revenue comparative period ambisome sale volume increase european union low pricing region slightly reduce related net product sale recognize expect total product sale market product continue grow continue expand sale marketing effort table content royalty revenue follow table summarize period period change royalty revenue thousand change change royalty revenue significant source royalty revenue sale tamiflu roche sale ambisome united states astellas royalty revenue million increase compare primarily drive recognition tamiflu royalty roche million increase tamiflu royalty high tamiflu sale record roche include sale relate pandemic planning initiative worldwide elimination contractual cost good adjustment result dispute resolution november historically reduce tamiflu royalty recognize recognize royalty tamiflu sale roche quarter follow quarter sell royalty revenue million increase compare primarily drive amount receive connection dispute resolution discuss recognition high royalty receive roche high tamiflu sale cause significant flu season particularly japan fulfillment order pandemic readiness supply certain country november resolve dispute roche relate development license agreement agree terminate relate arbitration pende roche relate dispute resolution roche pay million recognize royalty revenue consist million relate dispute royalty million relate reimbursement contractual cost good adjustment previously reduce earn royalty million relate update royalty payable month base thencurrent royalty rate instead prior year effective royalty rate royalty revenue earn roche include amount recognize dispute resolution million million respectively royalty revenue earn sale ambisome astella million seven percent decrease million contract revenue follow table summarize period period change contract revenue thousand change change contract revenue contract revenue million decrease compare contract revenue consist primarily net product distribution service revenue sale flolan million milestone payment receive osi pharmaceuticals inc osi relate commercial sale macugen european union revenue earn contract manufacturing project amortization previously defer milestone revenue contract revenue consist primarily million milestone payment earn osi relate commercial sale macugen united states revenue earn contract manufacturing project amortization previously defer milestone revenue table content cost good sell product gross margin follow table summarize period period change product sale thousand cost good sell thousand product gross margin change change total product sale cost good sell product gross margin product gross margin compare low gross margin primarily launch atripla united states million writedown inventory gilead access program estimate net realizable value product mix change patient continue switch viread high margin product truvada andor atripla partially offset low effective royalty rate result july emtricitabine royalty buyout discuss low api cost high average selling price hiv product united states atripla product sale decrease product gross margin correspond impact product gross profit primary beneficiary joint venture bms consolidate atripla product sale benefit product gross margin truvada portion atripla sustiva portion atripla product sale carry zero product gross profit joint venture purchase sustiva api bms bmss estimate net selling price sustiva market product gross margin compare primarily product mix change patient switch viread high margin product truvada prior july pay royalty emory worldwide net sale product contain emtrcitabine july royalty pharma purchase respectively royalty interest own emory exchange elimination royalty obligation result purchase capitalize million prepay royalty represent share million purchase price quarter begin amortize prepay royalty cost good sell remain life underlie patent base effective royalty rate derive forecast sale product contain emtricitabine record royalties royalty pharma base actual emtricitabine net sale relative royalty pharma ownership interest underlie emory royalty interest expect product gross margin lower drive high mix atripla product sale include sustiva portion zero product gross profit partially offset gross margin improvement drive low api cost continue benefit associate prepay emtricitabine royalty research development expense follow table summarize period period change major component rd expense year thousand change change research clinical development pharmaceutical development total research development rd expense consist primarily personnel cost include salary benefit stockbase compensation clinical study perform cro material supplies license fee overhead allocation consist support facility relate cost rd activity separate main category research clinical development pharmaceutical development research cost typically consist preclinical toxicology cost clinical development cost include cost phase clinical trial pharmaceutical development expense consist cost product formulation chemical analysis table content rd expense increase million compare primarily increase compensation benefit million largely high headcount include stockbase compensation expense million adoption sfas r january increase contract service clinical study expense million relate clinical product development research activity hiv hepatitis program newlyacquire program respiratory cardiopulmonary area high expense partially offset low milestone payment japan tobacco compare related licensing development lead integrase inhibitor candidate gs million payment emory connection amendment license agreement emory relate obligation develop emtricitabine hepatitis b indication general significant collaboration payment see payment japan tobacco emory period cause rd expense fluctuate period period rd expense increase million compare primarily million payment emory mention million payment japan tobacco relate execution hiv integrase license agreement gs increase compensation benefit million high headcount increase clinical product development activity associate hiv hepatitis program payment emory japan tobacco expense underlie technology incomplete alternative future use case emory significant rd activity expect year expect rd expense increase level reflect increase spending internal collaborative rd effort product licensing activity relate expectation product candidate progress advanced clinical trial especially respiratory cardiopulmonary area sell general administrative expense follow table summarize period period change sell general administrative sga expense year thousand change change sell general administrative sga expense increase million compare high expense primarily drive high headcount increase compensation benefit million include stockbase compensation expense million adoption sfas r january increase expense million contract service promotional program relate business growth business development activity activity prepare launch atripla million writeoff certain capital asset relate renovations corporate headquarter campus addition beginning begin report net foreign exchange transaction gain loss fair value change derivative instrument designate hedge interest income net amount previously report sga expense reclassify enhance comparability financial statement company prior year amount insignificant reclassify consistent current year presentation sga expense increase million compare increase primarily increase compensation benefit million largely high headcount increase market research speaker program symposia cost million million severance relocation expense associate relocation european commercial medical administrative headquarters france united kingdom increase medical education cost million increase journal advertising cost million cost relate general expansion sale marketing activity worldwide increase partially offset decrease bad debt expense million result high collection activity certain european country table content expect sga expense increase primarily high cost incur administrative activity sale marketing effort support business growth sale force expansion plan anticipate ambrisentan launch united states high cost relate ongoing investment global commercial organization additional hire promotional program incremental operating expense associate acquisition corus myogen purchase inprocess research development connection acquisition myogen corus record purchase inprocess research development iprd expense billion million respectively year end december purchase iprd expense myogen represent estimate fair value myogen incomplete research development program reach technological feasibility alternative future use acquisition date expense acquisition summary research development program acquisition date follow estimate acquisition date fair value program description status development millions ambrisentan orally active nonsulfonamide propanoic acidclass endothelin phase clinical trial complete prior acquisition date file nda receptor antagonist era treatment pulmonary arterial fda december february fda grant priority review hypertension status nda marketing approval ambrisentan establish target review date june darusentan orally active etaselective era treatment resistant phase clinical development acquisition date date filing hypertension estimate fair value purchase iprd determine income approach discount expect future cash flow present value estimate related future net cash flow present value riskadjuste discount rate significant assumption base estimate internal rate return myogen operation comparable estimate weighted average cost capital company myogen profile project cash flow ambrisentan darusentan program base key assumption estimate revenue operate profit relate program consider stage development time resource need complete development approval relate product life potential commercialize product associate risk include inherent difficulty uncertaintie develop drug compound obtain fda regulatory approval risk relate viability potential alternative treatment future target market purpose estimate fair value ambrisentan program estimate program approximately complete acquisition date base estimate time cost complete phase clinical trial complete base assumption incur future research development cost approximately million million date acquisition include year commercialization expect occur material net cash inflow estimate begin ambrisentan assume necessary regulatory approval received product successfully commercialize date table content purpose estimate fair value darusentan program estimate program approximately complete acquisition date base estimate time cost complete remain effort include completion phase clinical development prepare filing nda fda base assumption incur future research development cost approximately million million date acquisition include year commercialization expect occur material net cash inflow estimate begin darusentan assume necessary regulatory approval received product successfully commercialize date remain effort complete myogen iprd program primarily consist clinical trial cost length success extremely difficult predict obtain necessary regulatory approval numerous risk uncertainty exist prevent completion development include ability enroll patient clinical trial possibility unfavorable result clinical trial risk fail obtain fda regulatory body approval feedback regulatory authority result clinical trial require modification delay later stage clinical trial additional trial perform certain ambrisentan darusentan purchase myogen approve united states country outside united states marketing approval significant limitation use future discussion regulatory agency determine datum need timeline review differ materially current projection acquire product candidate development successfully commercialize result strategic decision discontinue development product candidate example believe commercialization difficult relative opportunity pipeline program complete timely basis prospect future revenue growth adversely impact assurance give underlie assumption forecast cash flow timely successful completion project materialize estimate reason actual result vary significantly estimate result purchase iprd expense corus represent estimate fair value coruss incomplete inhale aztreonam lysine cystic fibrosis research development program reach technological feasibility alternative future use acquisition date expense acquisition description program acquisition date follow estimate acquisition date fair value program description status development million inhale aztreonam lysine cystic fibrosis aztreonam formulation inhalation gramnegative phase clinical trial acquisition date date filing bacteria cause lung infection patient cystic fibrosis estimate fair value purchase iprd determine income approach discount expect future cash flow present value estimate related future net cash flow present value riskadjuste discount rate significant assumption base estimate internal rate return coruss operation comparable estimate weightedaverage cost capital company coruss profile project cash flow aztreonam lysine inhalation program base key assumption estimate revenue operate profit relate program consider stage development time resource need complete development approval relate product life potential commercialize product associate risk include inherent difficulty uncertaintie develop drug compound obtain fda regulatory approval risk relate viability potential alternative treatment future target market coruss earlystage candidate include valuation purchase iprd earlystage program identifiable revenue expense associate table content purpose estimate fair value aztreonam program estimate program approximately complete acquisition date base estimate time cost complete remain effort include completion phase clinical development prepare filing nda fda base assumption incur future research development cost approximately million million date acquisition include year commercialization expect occur material net cash inflow estimate begin aztreonam program assume necessary regulatory approval received product successfully commercialize date remain effort complete coruss iprd program primarily consist clinical trial cost length success extremely difficult predict obtain necessary regulatory approval numerous risk uncertainty exist prevent completion development include ability enroll patient clinical trial possibility unfavorable result clinical trial risk fail obtain fda regulatory body approval feedback regulatory authority result clinical trial require modification delay later stage clinical trial additional trial perform certain aztreonam lysine cystic fibrosis purchase corus approve united states country outside united states marketing approval significant limitation use future discussion regulatory agency determine datum need timeline review differ materially current projection acquire product candidate development successfully commercialize result strategic decision discontinue development product candidate example believe commercialization difficult relative opportunity pipeline program complete timely basis prospect future revenue growth adversely impact assurance give underlie assumption forecast cash flow timely successful completion project materialize estimate reason actual result vary significantly estimate result gain warrant pursuant march agreement eyetech pharmaceuticals inc eyetech predecessor osi receive warrant purchase share eyetech series b convertible prefer stock exercisable price share january eyetech complete initial public offering common stock time adjust fair value warrant result gain million time fair value warrant estimate blackschole valuation model volatility rate discount rate end quarter exercise warrant net basis share eyetech common stock consideration exercise price subsequently hold share eyetech common stock second quarter sell eyetech share own realize gain approximately million include interest income net makewhole payment convertible debt redemption october call redemption outstanding convertible senior note december convertible senior note redeem november provisional redemption base market price common stock exceed certain threshold aggregate principal outstanding note million convertible senior note redeemable redemption price equal principal note plus cash payment equal accrue unpaid interest redemption date cash makewhole payment equal principal value note interest actually pay accrue unpaid date issuance note redemption date interest convertible senior note cease accrue redemption date remain right holder receive redemption payment include accrue unpaid interest redemption date makewhole payment alternatively note holder elect convert note share common stock price share share common stock principal note holder substantially outstanding note convert table content note share common stock prior november redemption date result conversion share common stock issue note holder connection redemption aggregate makewhole payment million note holder classify consolidated statement operation interest income net record interest income net million million million respectively amount include reclassification net foreign exchange transaction gain loss discuss increase primarily attributable high average cash investment balance prior year interest income depend principally prevail interest rate level cash cash equivalent marketable security balance interest expense incur interest expense million compare million million april issue million principal convertible senior note note million principal convertible senior note note collectively note private placement pursuant rule securities act amend note note issue par bear interest rate respectively debt issuance cost million connection issuance note record noncurrent asset amortize interest expense straightline basis contractual term note increase interest expense primarily interest term loan enter december interest note decrease interest expense primarily attributable conversion million convertible senior note share common stock november expect interest expense decrease continue payment term loan minority interest joint venture minority interest joint venture consolidated financial statement reflect bmss interest operating result joint venture bms united states primary beneficiary joint venture determine financial accounting standard board fasb interpretation consolidation variable interest entity consolidate operation joint venture consolidated financial statement operation joint venture commence activity primarily focus coformulation oncedaily single tablet regimen achieve bioequivalence coformulation achieve bioequivalence formulation single tablet regiman end nda file april single tablet regimen july receive approval fda single tablet regimen united states give trade atripla provision income taxis provision income taxis million million million respectively include operate income pretax charge million billion purchase iprd expense associate corus myogen acquisition respectively effective tax rate differ federal statutory rate primarily federal tax nondeductible purchase iprd expense state taxis offset tax credit certain operating earning nonus subsidiary consider indefinitely invest outside united states effective tax rate differ federal statutory rate generally state taxis offset recognition previously unbenefitte net operating loss tax credit carryforward certain operating earning nonus subsidiary consider indefinitely invest outside united states onetime benefit qualifying dividend american job creation act ajca table content october ajca sign law ajca allow deduction certain qualified foreign earning repatriate define ajca elect apply provision qualify earning repatriate earning repatriation result onetime tax provision benefit approximately million recognize effective income tax rate differ federal statutory rate generally recognition previously unbenefitte net operating loss tax credit carryforward certain earning operation jurisdiction low tax rate united states jurisdiction taxis provide earning plan reinveste indefinitely outside united states partially offset state taxis june fasb issue fasb interpretation accounting uncertainty income taxis fin interpretation sfas accounting income taxis sfas fin clarifie accounting uncertainty income taxis recognize enterprise financial statement accordance sfas prescribe minimum recognition threshold measurement attribute financial statement recognition measurement tax position take expect take tax return fin provide guidance derecognition classification interest penalty account interim period disclosure transition fin effective fiscal year begin december adopt fin january require preliminary determination impact adopt standard range million million actual record charge accumulate deficit consolidate balance sheet adoption fin liquidity capital resource follow table summarize cash cash equivalent marketable security work capital cash flow activity end year thousand december cash cash equivalent marketable security working capital year end december cash provide operating activity invest activity financing activity cash cash equivalent marketable security cash cash equivalent marketable security total billion december decrease december decrease million primarily net cash pay billion acquisition myogen raylo corus cash million pay principal outstanding term loan decrease partially offset net cash provide operation billion net proceed million issuance note relate transaction proceed issuance stock employee stock plan million table content cash cash equivalent marketable security total billion december increase december increase billion primarily net cash provide operation million proceed million term loan enter proceed issuance stock employee stock plan million increase partially offset capital expenditure million work capital work capital december billion compare billion december significant factor result decrease work capital billion decrease cash cash equivalent shortterm marketable security primarily need fund significant acquisition activity decrease marketable security portfolio decrease result classification certain marketable security longterm security million increase account payable primarily launch atripla july relate purchase sustiva api bms bmss approximate market value sustiva order joint venture build inventory level supply increase atripla demand work capital decrease partially offset million increase inventory primarily increase atripla inventory include sustiva api bmss approximate market value sustiva million increase account receivable primarily increase sale low receivables collection certain european country collection traditionally slow work capital december billion compare billion december significant factor result increase work capital billion increase cash cash equivalent marketable security million increase inventory meet grow demand hiv product hepsera meet gilead access program requirement million increase prepaid current asset primarily relate current portion prepay royalty emory emtricitabine million increase defer tax asset million increase account receivable primarily increase sale partially offset high collection activity especially certain european country collection traditionally slow increase partially offset million increase income taxis payable primarily high profitability partially offset tax benefit employee stock plan million increase reflect current portion million term loan enter december million increase accrue liability include increase accrual relate medicaid rebate royalty expense sale marketing expense partially offset decrease liability associate fair value forward currency contract dollar strengthen euro table content cash provide operating activity cash provide operating activity billion comprise primarily billion net loss adjust noncash item billion purchase iprd expense stockbase compensation expense million million tax benefit relate employee stock plan partially offset million excess tax benefit stock option exercise million net cash outflow relate change operate asset liability include million increase inventory partially offset million increase account payable relate primarily increase atripla inventory mention million increase account receivable product sale growth low receivables collection certain european country collection traditionally slow cash provide operating activity million comprise primarily million net income adjust noncash item million tax benefit employee stock plan million net cash outflow relate change operate asset liability include million prepay royalty emory relate emtricitabine cash provide operating activity million comprise primarily million net income adjust noncash item million defer income taxis primarily result utilization net operating loss tax credit carryforward offset taxable income partially offset million net cash outflow relate change operate asset liability include million increase account receivable primarily result product sale growth cash investing activity cash investing activity primarily relate purchase sale maturity availableforsale security acquisition myogen raylo corus capital expenditure cash investing activity primarily relate purchase sale maturity availableforsale security billion cash investing activity compare million million increase cash investing activity primarily result acquisition myogen raylo corus total billion net cash billion provide sale maturity purchase availableforsale security compare net cash million million net cash investing activity include capital expenditure million million invest nonmarketable security issue certain strategic partner capital expenditure related primarily expand certain aspect manufacturing capability upgrade facility additional spending computer laboratory equipment accommodate continued growth capital expenditure include purchase building previously lease foster city california headquarters table content cash provide financing activity april issue million principal convertible senior note million principal convertible senior note collectively note private placement pursuant rule securities act amend net proceed note issuance billion deducting initial purchaser discount estimate offering expense repurchase million common stock concurrent issuance note purchase convertible note hedge private transaction cost million sell warrant acquire million share common stock private transaction receive net proceed million take convertible note hedge warrant intend reduce potential dilution future conversion note effectively increase initial conversion price note total transaction generate net proceed million cash provide financing activity million primarily result million net proceed generate issuance note relate transaction mention addition receive proceed employee stock option exercise million million excess tax benefit stock option exercise cash inflow partially offset million pay principal term loan cash provide financing activity primarily relate proceed million term loan million stock option exercise stock purchase employee stock plan cash provide financing activity primarily relate million proceed stock option exercise stock purchase employee stock purchase plan information december uncollateralize revolving credit facility million outstanding amount capacity revolve credit facility continue increase maximum million commensurate repayment principal term loan believe exist capital resource supplement cash generate operation adequate satisfy capital need foreseeable future future capital requirement depend factor include limited follow commercial performance current future product progress scope rd effort include preclinical study clinical trial cost timing outcome regulatory review expansion sale marketing capability administrative expense possibility acquire manufacturing capability additional office facility possibility acquire company new product establishment additional collaborative relationship company defense cost associate settlement adverse result litigation government investigation future require additional funding form proceed equity debt financing fund require assure available favorable term offbalance sheet arrangement offbalance sheet arrangement currently material reasonably likely material financial position result operation table content contractual obligation contractual obligation consist debt obligation capital operating lease purchase obligation primarily form capital commitment purchase obligation active pharmaceutical ingredient inventoryrelate item clinical trial contract follow table summarize significant enforceable legally bind obligation future commitment obligation relate contract likely continue regardless fact cancelable december thousands payment period contractual obligation total year year year year convertible senior note term loan capital lease obligation operating lease obligation capital commitment purchase obligation clinical trial total december outstanding principal billion note issue april december outstanding principal million million fiveyear term loan enter december december firm capital project commitment approximately million primarily relate expansion certain aspect manufacturing capability upgrade facility december firm commitment purchase active pharmaceutical ingredient inventoryrelate item amount disclose represent minimum purchase requirement actual purchase expect significantly exceed amount december clinical study clinical trial phase significant clinical trial expenditure cro contract cro cancelable generally cancel contract amount reflect commitment base exist contract reflect future modification exist contract anticipate potential new contract exclude interest relate payment convertible senior note term loan capital lease obligation addition commit potential future milestone payment thirdpartie license development program payment agreement generally payable achievement certain developmental regulatory andor commercial milestone achievement milestone probable reasonably estimable contingency record consolidated balance sheet include table recent accounting pronouncement june fasb issue fasb interpretation accounting uncertainty income taxis fin interpretation sfas accounting income taxis sfas fin clarifie accounting uncertainty income taxis recognize enterprise financial statement accordance sfas prescribe minimum recognition threshold measurement attribute financial statement recognition measurement tax position take expect take tax return fin provide guidance derecognition classification interest penalty account interim period disclosure transition fin effective fiscal year begin december adopt fin january require preliminary determination impact adopt standard range million million actual record charge accumulate deficit consolidate balance sheet adoption fin table content item quantitative qualitative disclosure market risk foreign currency exchange risk operation include manufacture sale activity united states canada ireland sale activity country outside united states include europe australia result financial result significantly affect factor change foreign currency exchange rate weak economic condition foreign market distribute product operating result expose change exchange rate dollar foreign currency significant euro british pound australian dollar dollar strengthen currency relative value sale respective foreign currency decrease conversely dollar weaken relative amount sale increase overall net receiver foreign currency benefit weak dollar adversely affect strong dollar relative foreign currency transact significant amount business enter foreign exchange forward contract mitigate impact change currency exchange rate cash flow sale denominate foreign currency foreign currencydenominate net monetary asset liabilitie significant percentage product sale denominate foreign currency increase value dollar foreign currency past reduce future reduce dollar return sale negatively impact financial condition use forward contract hedge percentage forecast international sale primarily denominate euro currency recent year foreign currency exchange fluctuation positively negatively impact product sale gross margin impact foreign currency fluctuation moderated hedge program follow table summarize notional amount average currency exchange rate fair value open foreign exchange forward contract december contract maturity year average rate state term foreign currency dollar fair value represent estimate settlement amount december notional amount fair value dollar thousand currency notional average rate fair value british pound euro australian dollar total total notional billion total fair value liability million open foreign exchange forward contract december compare total notional million total fair value relate asset million open foreign exchange forward contract december interest rate risk portfolio availableforsale marketable security fix variablerate liability create exposure interest rate risk respect investment portfolio adhere investment policy require limit amount invest security base duration industry group investment type issuer security issue government goal investment policy order priority follow safety preservation principal diversification risk liquidity investment sufficient meet cash flow requirement competitive aftertax rate return table content follow table summarize expect maturity average interest rate interestgenerate asset interestbeare liability december dollar thousand year end december total fair value december asset availableforsale debt security average interest rate liability convertible senior note average interest rate term loan include current portion average interest rate capital lease obligation include current portion average interest rate april issue million principal convertible senior note note million principal convertible senior note note private placement pursuant rule securities act amend note note issue par bear interest rate respectively convert subject certain circumstance december enter million fiveyear term loan average interest rate base imply threemonth libor forward rate yield curve december option choose borrow maturity base sixmonth libor term loan minimum principal repay end calendar quarter begin march percent outstanding interest accrue rate libor plus tiere contractual rate basis point prepay term loan time accrue interest prepay principal penalty premium year end december million term loan principal repay outstanding interest principal december payable demand international credit risk account receivable balance december million compare million december growth account receivable balance primarily high product sale hiv product united states europe certain country payment typically slow primarily greece italy portugal spain aggregate account receivable balance significant case slow payment practice reflect pace governmental entity reimburse customer turn increase credit risk relate certain customer sale customer country tend relatively slowpaye past increase future increase average length time account receivable outstanding december past account receivable greece italy portugal spain total million million day past base contractual term receivables date experience significant loss respect collection account receivable believe substantially account receivable balance collectible perform credit evaluation customer financial condition generally require collateral table content item financial statement supplementary datum financial statement require item set forth begin report incorporate reference item change disagreement accountant account financial disclosure applicable item control procedure evaluation disclosure control procedure evaluation december carry supervision participation management include chief executive officer chief financial officer effectiveness design operation disclosure control procedure define sec rule control procedure company design ensure information require disclose company report file securities exchange act amended exchange act record process summarize report require time period base evaluation chief executive officer chief financial officer conclude disclosure control procedure effective b management report internal control financial reporting management responsible establish maintain adequate internal control financial reporting term define exchange act rule af internal control system design provide reasonable assurance preparation fair presentation financial statement external purpose accordance generally accept accounting principle internal control system matter design inherent limitation provide reasonable assurance objective internal control system meet supervision participation management include chief executive officer chief financial officer conduct evaluation effectiveness internal control financial reporting base criterion establish internal controlintegrate framework issue committee sponsor organization treadway commission coso base evaluation conclude internal control financial reporting effective december independent register public accounting firm ernst young llp audit consolidated financial statement include annual report issue report management assessment internal control financial reporting effectiveness internal control financial reporting december report audit internal control financial reporting appear table content report independent register public accounting firm board director stockholder gilead sciences inc audit management assessment include accompany management report internal control financial reporting gilead sciences inc maintain effective internal control financial reporting december base criterion establish internal controlintegrate framework issue committee sponsor organization treadway commission coso criterion gilead sciences incs management responsible maintain effective internal control financial reporting assessment effectiveness internal control financial reporting responsibility express opinion management assessment opinion effectiveness company internal control financial reporting base audit conduct audit accordance standard public company accounting oversight board united states standard require plan perform audit obtain reasonable assurance effective internal control financial reporting maintain material respect audit include obtain understand internal control financial reporting evaluate management assessment testing evaluate design operating effectiveness internal control perform procedure consider necessary circumstance believe audit provide reasonable basis opinion company internal control financial reporting process design provide reasonable assurance reliability financial reporting preparation financial statement external purpose accordance generally accept accounting principle companys internal control financial reporting include policy procedure pertain maintenance record reasonable detail accurately fairly reflect transaction disposition asset company provide reasonable assurance transaction record necessary permit preparation financial statement accordance generally accept accounting principle receipt expenditure company accordance authorization management director company provide reasonable assurance prevention timely detection unauthorized acquisition use disposition company asset material effect financial statement inherent limitation internal control financial reporting prevent detect misstatement projection evaluation effectiveness future period subject risk control inadequate change condition degree compliance policy procedure deteriorate opinion management assessment gilead sciences inc maintain effective internal control financial reporting december fairly state material respect base coso criterion opinion gilead sciences inc maintain material respect effective internal control financial reporting december base coso criterion audit accordance standard public company accounting oversight board united states consolidated balance sheet gilead sciences inc december relate consolidated statement operation stockholder equity cash flow year period end december relate financial statement schedule report date february express unqualified opinion thereon ernst young llp palo alto california february table content c change internal control financial reporting management include chief executive officer chief financial officer evaluate change internal control financial reporting occur quarter end december conclude change quarter materially affect reasonably likely materially affect internal control financial reporting item b information applicable iii item director executive officer corporate governance information require item concern director executive officer incorporate reference section definitive proxy statement file sec pursuant regulation connection annual meeting stockholder proxy statement heading nominee board committee meeting executive officer section beneficial ownership reporting compliance write code ethic apply director employee include executive officer include limitation principal executive officer principal financial officer principal accounting officer controller person perform similar function code ethic available website httpwwwinvestorsgileadcom corporate governance change waiver code ethic disclose website intend satisfy disclosure requirement item form k amendment waiver provision code ethic disclose information website item executive compensation information require item incorporate reference section proxy statement heading executive compensation compensation committee interlock insider participation compensation committee report compensation nonemployee directors item security ownership certain beneficial owner management relate stockholder matter information require item incorporate reference section proxy statement heading security ownership certain beneficial owner management security authorize issuance equity compensation plan item certain relationship relate transaction director independence information require item incorporate reference section proxy statement heading nominee certain relationship relate transaction item principal accountant fee service information require item incorporate reference section proxy statement head principal accountant fee service table content iv item exhibit financial statement schedule follow document file annual report index list consolidate financial statement report independent register public accounting firm audit consolidated financial statement consolidate balance sheet consolidate statement operation consolidate statement stockholder equity consolidate statement cash flow note consolidated financial statement schedule ii include report schedule omit require require information include financial statement note thereto exhibit follow exhibit file herewith incorporate reference exhibit exhibit footnote number description document asset purchase agreement registrant osi pharmaceuticals inc date november agreement plan merger registrant simbolo acquisition sub inc whollyowne subsidiary registrant triangle pharmaceuticals inc date december agreement plan merger registrant gryphon acquisition sub inc corus pharma inc rodney ferguson phd chairman behalf stockholder representative committee date april stock purchase agreement registrant degussa ag laporte nederland bv raylo chemicals inc date june agreement plan merger registrant mustang merger sub inc myogen inc date october restate certificate incorporation registrant amend certificate amendment restate certificate incorporation registrant certificate designation series junior participate prefer stock registrant amendment certificate designation series junior participate prefer stock registrant amend restate bylaw registrant amend restate december reference exhibit exhibit exhibit exhibit amend restate right agreement registrant chasemellon shareholder services llc date october amendment amend restate right agreement registrant mellon investor service llc know chasemellon shareholder services llc date october table content exhibit exhibit footnote number description document second amendment amend restate right agreement registrant mellon investor service llc know chasemellon shareholder services llc date indenture relate convertible senior note registrant wells fargo bank national association trustee include form convertible senior note date april indenture relate convertible senior note registrant wells fargo bank national association trustee include form convertible senior note date april registration right agreement registrant merrill lynch pierce fenner smith incorporate morgan stanley co incorporate banc america securities llc goldman sachs co inc date april form indemnity agreement enter registrant director executive officer form employee proprietary information invention agreement enter registrant certain officer key employee form employee proprietary information invention agreement enter registrant certain officer key employee revise september form option agreement stock option plan letter agreement registrant iocbrega date september registrant employee stock purchase plan amend july registrant stock option plan relate agreement amend restate april amend january amend january registrants nonemployee directors stock option plan include form option agreement thereunder amend january amend january amendment agreement registrant iocbrega date october amendment agreement registrant iocbrega date december development license agreement registrant f hoffmannla roche ltd hoffmannla roche inc date september nexstar pharmaceutical incs incentive stock plan adopt february amend nexstar pharmaceutical inc director option plan adopt july license distribution agreement dainippon sumitomo pharma co ltd successor sumitomo pharmaceuticals co ltd registrant successor nexstar pharmaceuticals inc date september settlement agreement registrant successor nexstar pharmaceuticals inc astellas pharma inc successor fujisawa usa inc liposome company inc date august amendment date april sumitomo pharmaceutical co ltd registrant successor nexstar pharmaceuticals inc license distribution agreement date september sumitomo registrant successor nexstar pharmaceuticals inc gilead sciences inc defer compensation planbasic plan document table content exhibitexhibit footnote number description document gilead sciences inc defer compensation planadoption agreement addendum gilead sciences inc defer compensation plan license agreement gilead world market limited glaxo group limit date april triangle pharmaceuticals inc stock incentive plan exclusive license agreement registrant successor triangle pharmaceuticals inc glaxo group limited wellcome foundation limited glaxo wellcome inc emory university date settlement agreement registrant successor triangle pharmaceuticals inc emory university dr david w barry glaxo wellcome plc glaxo wellcome inc glaxo group limited wellcome foundation limited date settlement exclusive license agreement registrant successor triangle pharmaceuticals inc shire biochem inc shire pharmaceuticals group plc emory university university georgia research foundation date august master clinical commercial supply agreement gilead world markets ltd registrant patheon inc date january licensing agreement registrant osi pharmaceuticals inc successor eyetech pharmaceuticals inc date march amend december april amendment licensing agreement eyetech pharmaceuticals inc registrant date amendment licensing agreement osi pharmaceuticals inc successor eyetech pharmaceuticals inc registrant date december amendment licensing agreement osi pharmaceuticals inc successor eyetech pharmaceuticals inc registrant date august amendment date license agreement date april glaxo group limited gilead world market limited license agreement japan tobacco inc registrant date march tenofovir disoproxil fumarate manufacturing supply agreement gilead world markets ltd pharmachem technologies grand bahama ltd date july royalty sale agreement registrant emory university investor trust custodial service ireland limit solely capacity trustee royalty pharma date july amend restate license agreement registrant emory university investor trust custodial service ireland limit solely capacity trustee royalty pharma date july term loan agreement gilead biopharmaceutics ireland corporation lenders party thereto bank america na administrative agent date december parent guaranty agreement registrant date december favor bank america na connection term loan agreement subsidiary guaranty agreement gilead vintage park llc connection term loan agreement date december table content exhibitexhibit footnote number description document credit agreement registrant lender party thereto bank america na administrative agent swing line lender lc issuer date december subsidiary guaranty agreement gilead vintage park llc date december connection credit agreement form employee stock option agreement equity incentive plan form nonemployee stock option agreement equity incentive plan gilead sciences inc corporate bonus plan amendment supplement date november development licensing agreement registrant f hoffmannla roche ltd hoffmanla roche inc date september restate amend toll manufacturing agreement gilead sciences limited registrant altana pharma oranienburg gmbh date november amend restate agreement registrant successor vestar inc astellas pharma inc successor fujisawa usa inc date june gilead sciences inc severance plan amend gilead sciences inc equity incentive plan amend gilead sciences inc code section bonus plan gilead sciences inc defer compensation plan confirmation otc convertible note hedge relate note date april amend restate april registrant bank america na confirmation otc convertible note hedge relate note date april amend restate april registrant bank america na confirmation otc warrant transaction date april amend restate april registrant bank america na warrants expire confirmation otc warrant transaction date april amend restate april registrant bank america na warrant expire emtricitabine manufacturing supply agreement gilead sciences limited degussa ag date june corus pharma inc stock plan form corus pharma inc stock plan stock option agreement form restrict award agreement equity incentive plan sixth amendment agreement license agreement institute organic chemistry biochemistry academy sciences czech republic k u leuven research development registrant date august amend restate collaboration agreement registrant gilead holding llc bristolmyers squibb company er squibb son llc bristolmyers squibb gilead sciences llc date september base salary name executive officer form performance share award agreement equity incentive plan license agreement myogen inc abbott laboratories date june table content exhibit exhibit footnote number description document license agreement abbott deutschland holding gmbh company date october license agreement myogen glaxo group limit date march subsidiary registrant consent independent register public accounting firm power attorney reference signature section certification section certification section certification file exhibit registrant current report form k file january incorporate reference file exhibit registrant current report form k file december incorporate reference file exhibit registrant quarterly report form q quarter end september incorporate reference file exhibit registrant quarterly report form q quarter end june incorporate reference file exhibit registrant current report form k file october incorporate reference file exhibit registrant registration statement form file july incorporate reference file exhibit registrant report form k file incorporate reference file exhibit registrant report form k file november incorporate reference file exhibit registrant current report form k file october incorporate reference file exhibit registrant current report form k file october incorporate reference file exhibit registrant registration statement form file june incorporate reference file exhibit registrant current report form k file april incorporate reference file exhibit registrant registration statement form amend incorporate reference file exhibit registrant fiscal year end december incorporate reference file exhibit registrant registration statement form file january incorporate reference file exhibit registrant annual report fiscal year end december incorporate reference file exhibit registrant annual report fiscal year end march incorporate reference file exhibit registrant fiscal year end december incorporate reference file exhibit nexstar pharmaceutical inc quarterly report form q quarter end june incorporate reference table content file exhibit nexstar pharmaceutical inc form q quarter end september incorporate reference file exhibit nexstar pharmaceutical inc fiscal year end december incorporate reference file exhibit nexstar pharmaceutical inc form q quarter end september incorporate reference file exhibit nexstar pharmaceutical inc form q quarter end june incorporate reference file exhibit registrant fiscal year end december incorporate reference file exhibit registrant quarterly report form q quarter end june incorporate reference file exhibit registrant registration statement form file january incorporate reference file exhibit triangle pharmaceutical inc quarterly report form q quarter end september incorporate reference file exhibit triangle pharmaceutical inc current report form k file september incorporate reference file exhibit registrant fiscal year end december incorporate reference file exhibit registrant form q quarter end march incorporate reference file exhibit registrant form q quarter end september incorporate reference file exhibit registrant current report form k file december incorporate reference file exhibit registrant current report form k file february incorporate reference file exhibit registrant form q quarter end march incorporate reference file exhibit registrant registration statement form file august incorporate reference file exhibit registrant current report form k file january incorporate reference file exhibit myogen inc registration statement form amend originally file august incorporate reference file exhibit myogen inc quarterly report form q file incorporate reference management contract compensatory plan arrangement require file pursuant item b certain confidential portion exhibit omit mean mark portion asterisk mark exhibit file separately secretary sec mark pursuant registrant application request confidential treatment rule b securities exchange act table content gilead sciences inc consolidated financial statement year end december content report independent register public accounting firm audit consolidated financial statement consolidate balance sheet consolidate statement operation consolidate statement stockholder equity consolidate statement cash flow note consolidated financial statement table content report independent register public accounting firm board director stockholder gilead sciences inc audit accompany consolidated balance sheet gilead sciences inc december relate consolidated statement operation stockholder equity cash flow year period end december audits include financial statement schedule list index item financial statement schedule responsibility company management responsibility express opinion financial statement schedule base audit conduct audits accordance standard public company accounting oversight board united states standard require plan perform audit obtain reasonable assurance financial statement free material misstatement audit include examine test basis evidence support amount disclosure financial statement audit include assess accounting principle significant estimate management evaluate overall financial statement presentation believe audits provide reasonable basis opinion opinion financial statement refer present fairly material respect consolidate financial position gilead sciences inc december consolidate result operation cash flow year period end december conformity generally accept accounting principle opinion relate financial statement schedule consider relation basic financial statement take present fairly material respect information set forth discuss note consolidated financial statement gilead sciences inc change method accounting stockbase compensation accordance guidance provide statement financial accounting standard r sharebase payment audit accordance standard public company accounting oversight board united states effectiveness gilead sciences inc internal control financial reporting december base criterion establish internal controlintegrate framework issue committee sponsor organization treadway commission report date february express unqualified opinion thereon ernst young llp palo alto california february table content gilead sciences inc consolidated balance sheet thousand share amount december asset current asset cash cash equivalent shortterm marketable security account receivable net allowance december december inventory defer tax asset prepay expense current asset total current asset property plant equipment net noncurrent portion prepay royalty noncurrent defer tax asset longterm marketable security minority interest joint venture noncurrent asset total asset liability stockholder equity current liability account payable accrue clinical preclinical expense accrue compensation employee benefit income taxis payable accrue liability defer revenue current portion longterm obligation total current liability longterm defer revenue convertible senior note longterm obligation minority interest joint venture commitment contingency stockholder equity prefer stock par value share share authorize outstanding common stock par value share share authorize share issue outstanding december respectively additional paidin capital accumulate comprehensive income defer stock compensation retain earning accumulate deficit total stockholder equity total liability stockholder equity accompany note table content gilead sciences inc consolidated statement operation thousand share amount year end december revenue product sale royalty revenue contract revenue total revenue cost expense cost good sell research development sell general administrative purchase inprocess research development total cost expense income loss operation gain warrant makewhole payment convertible debt redemption interest income net interest expense minority interest joint venture income loss provision income taxis provision income taxis net income loss net income loss sharebasic share share calculationbasic net income loss sharedilute share share calculationdilute accompany note table content gilead sciences inc consolidated statement stockholder equity thousand common stock accumulate retain additional defer earning total paidin comprehensive stock accumulate stockholder share capital income loss compensation deficit equity balance december net income unrealize loss availableforsale security net tax foreign currency translation adjustment unrealize loss cash flow hedge net tax comprehensive income conversion convertible senior note net debt issuance cost issuance employee stock purchase plan stock option exercise net tax benefit employee stock plan amortization defer stock compensation compensatory stock transaction balance december net income unrealize loss availableforsale security net tax foreign currency translation adjustment unrealize gain cash flow hedge net tax comprehensive income issuance employee stock purchase plan stock option exercise net tax benefit employee stock plan amortization defer stock compensation compensatory stock transaction balance december net loss unrealize gain availableforsale security net tax foreign currency translation adjustment unrealize loss cash flow hedge net tax comprehensive loss issuance employee stock purchase plan stock option exercise net tax benefit employee stock plan reversal defer stock compensation compensatory stock transaction assumption stock option connection acquisition purchase convertible note hedge sale warrant defer tax asset convertible note hedge repurchase common stock balance december ac compan ing note table content gilead sciences inc consolidated statement cash flow thousands year end december operating activity net income loss adjustment reconcile net income loss net cash provide operating activity depreciation amortization purchase inprocess research development stockbase compensation expense excess tax benefit stockbase compensation tax benefit employee stock plan asset impairment gain warrant defer income taxis writedown inventory minority interest joint venture otherthan temporary loss marketable security noncash transaction change operate asset liability account receivable net inventory prepay royalty prepay expense asset account payable income taxis payable accrue liability defer revenue minority interest joint venture net cash provide operating activity invest activity purchase marketable security proceed sale marketable security proceed maturitie marketable security acquisition net cash acquire purchase nonmarketable equity security capital expenditure net cash investing activity financing activity proceed issuance common stock proceed term loan net issuance cost proceeds issuance convertible senior note net issuance cost proceed sale warrant purchase convertible note hedge repurchase common stock repayment longterm debt obligation excess tax benefit stockbase compensation net cash provide financing activity effect exchange rate change cash net increase cash cash equivalent cash cash equivalent begin year cash cash equivalent end year supplemental disclosure cash flow information interest pay income taxis pay noncash investing financing activity common stock issue conversion debt reclassification achillion equity investment noncurrent asset marketable security achillion initial public offering reclassification defer debt issuance cost additional paidin capital conversion debt accompany note table content gilead sciences inc note consolidated financial statement december organization summary significant accounting policy overview gilead sciences inc gilead incorporate delaware june biopharmaceutical company discover develop commercialize innovative therapeutic area unmet medical need mission advance care patient suffer lifethreatening disease worldwide headquarter foster city california marketing operation north america europe australia date focus effort bring market novel therapeutic treatment lifethreatene infectious disease expand research development commercial focus include respiratory cardiopulmonary disease acquisition myogen inc myogen corus pharma inc corus currently market truvada emtricitabine tenofovir disoproxil fumarate viread tenofovir disoproxil fumarate atripla efavirenz mgemtricitabine mgtenofovir disoproxil fumarate mg emtriva emtricitabine treatment human immunodeficiency virus hiv infection hepsera adefovir dipivoxil treatment chronic hepatitis b infection ambisome amphotericin b liposome injection treatment fungal infection vistide cidofovir injection treatment cytomegalovirus cmv infection flolan epoprostenol sodium treatment pulmonary hypertension f hoffmanla roche ltd f hoffmanla roche inc roche market tamiflu oseltamivir phosphate treatment influenza royalty pay collaborative agreement manufacture macugen pegaptamib sodium injection manufacturing agreement osi pharmaceuticals inc osi sell macugen treatment neovascular agerelate macular degeneration royalty pay collaborative agreement basis presentation accompany consolidated financial statement include account gilead wholly own subsidiary joint venture bristolmyer squibb company bms primary beneficiary determine financial accounting standard board fasb interpretation consolidation variable interest entity fin r record minority interest consolidate financial statement reflect bmss interest joint venture significant intercompany transaction eliminate certain prior year amount reclassify consistent current year presentation january begin report net foreign exchange transaction gain loss fair value change derivative instrument designate hedge interest income net consolidated statement operation amount million million year end december respectively previously report sell general administrative sga expense reclassify conform current year presentation additionally begin classify interest receivable relate marketable security current asset consolidate balance sheet reclassification effect increase current asset decrease marketable security million december consolidate statement cash flow year end december reclassification effect decrease net cash investing activity decrease net cash provide operating activity million million respectively reclassification affect consolidated statement operation result issuance convertible senior note relate transaction april note cash cash equivalent marketable security increase significantly net proceed transaction consider exist cash cash equivalent marketable security credit facility note anticipate significant cash outflow ability hold longterm marketable table content gilead sciences inc note consolidated financial statementscontinue december security respective maturity significantly enhance accordingly quarter end june begin prospectively classify marketable security portfolio shortterm longterm base contractual maturity significant accounting policy estimate judgment preparation consolidated financial statement require estimate judgment affect report amount asset liability revenue expense related disclosure ongoing basis management evaluate estimate include related revenue recognition allowance doubtful account inventory prepay royalty clinical trial accrual tax provision stockbase compensation base estimate historical experience market specific relevant assumption believe reasonable circumstance result form basis make judgment carry value asset liability readily apparent source actual result differ significantly estimate revenue recognition product sale recognize revenue product sale persuasive evidence arrangement exist delivery customer occur price fix determinable collectibility reasonably assure recognition revenue product sale provision government rebate customer incentive cash discount prompt payment certain distributor fee estimate future return product expire appropriate item deduct gross product sale government rebate estimate amount payable governmentmanage medicaid program certain qualify federal state government program base contractual term historical utilization rate new information change program regulation guideline impact actual rebate expectation future utilization rate program channel inventory datum obtain major wholesaler accordance inventory management agreement government rebate invoice directly record accrue liability consolidate balance sheet qualified program purchase product wholesaler low contractual government price wholesaler charge difference acquisition cost low price record allowance account receivable cash discount estimate cash discount base contractual term historical utilization rate expectation future utilization rate distributor fee inventory management agreement significant wholesaler pay wholesaler fee primarily compliance certain contractuallydetermine covenant maintenance agreedupon inventory level distributor fee base contractuallydetermine fix percentage sale table content gilead sciences inc note consolidated financial statementscontinue december product return provide customer general right product return permit return product damage defective receive customer product unite state expired accept product return united states expire year expiration estimate expect return expire product base primarily ongoing analysis historical return pattern royalty revenue royalty revenue sale ambisome recognize month follow month correspond sale occur royalty revenue sale product recognize receive quarter follow quarter correspond sale occur contract revenue contract revenue research development rd record performance occur earning process complete base performance requirement contract nonrefundable contract fee performance obligation exist continue involvement gilead recognize early payment receive collection reasonably assure revenue nonrefundable upfront license fee milestone payment continue involvement development collaboration obligation supply product recognize performance occur obligation complete accordance specific term gilead obligation type arrangement revenue recognize obligation fulfil ratably development manufacturing period revenue associate substantive atrisk milestone recognize base achievement milestone define respective agreement advance payment receive excess amount earn classified defer revenue consolidated balance sheet contract revenue include revenue product distribution service net recognize persuasive evidence arrangement exist delivery customer occur price fix determinable collectibility reasonably assure accordance emerge issue task force eitf issue report revenue gross principal versus net agent record product distribution service revenue net supply price pay manufacturerlicensor distribution fee pay specialty pharmacy allowance product return cash discount government rebate contract revenue consolidated statement operation shipping handle cost shipping handling cost incur inventory purchase product shipment record cost good sell consolidated statement operation research development expense major component rd expense consist personnel cost include salary benefit stockbase compensation clinical study perform clinical research organization cro material supplies license fee overhead allocation consist administrative facility relate cost rd activity separate main category research clinical development pharmaceutical development research cost typically consist preclinical toxicology cost clinical development cost include cost phase clinical trial pharmaceutical development cost consist expense incur product formulation chemical analysis table content gilead sciences inc note consolidated financial statementscontinue december charge rd cost include clinical study cost expense incur consistent statement financial accounting standard sfas accounting research development cost cost significant component rd expense clinical study perform thirdparty cro accrue cost clinical study perform cro straightline basis service period specify contract adjust estimate require base go review level effort cost actually incur cro monitor level performance significant contract include extent patient enrollment activity communication cro adjust estimate require quarterly basis expense reflect actual effort expend cro material cro contract terminable write notice generally liable actual effort expend cro point time contract regardless payment status amount pay advance service perform refunded contract terminate contract include additional termination payment payable terminate contract additional termination payment record contract terminate advertising expense expense cost advertising include promotional expense incur advertising expense million million million earning loss share basic earning loss share calculate base weightedaverage number share common stock outstanding period dilute earning loss share calculate base weightedaverage number share common stock dilutive security outstanding period potential dilutive share common stock result assume exercise outstanding stock option equivalent assume conversion convertible senior note note convertible senior note note collectively note assume exercise warrant relate note determine treasury stock method follow table reconciliation numerator denominator calculation basic diluted earning loss share thousands year end december numerator net income loss calculation basic earning loss share interest expense makewhole payment convertible note redemption net income loss calculation dilute earning loss share denominator weightedaverage common share outstanding calculation basic earning loss share effect dilutive security stock option equivalent convertible senior note weightedaverage common share outstanding calculation dilute earning loss share table content gilead sciences inc note consolidated financial statementscontinue december stock option purchase approximately million million weightedaverage share common stock outstanding year end december respectively include computation dilute earning share option exercise price great average market price common stock period effect antidilutive net loss approximately million weightedaverage number outstanding stock option common stock equivalent include computation dilute net loss share inclusion antidilutive addition inclusion restriction conversion note dilute earning loss share computation effect dilution conversion note share price common stock exceed note note respectively stockbase compensation december fasb issue sfas revise sharebased payment sfas r revision sfas accounting stockbase compensation sfas require sharebased payment employee director include grant stock option recognize consolidated statement operation base fair value begin quarterly period fiscal year begin june early adoption permit sfas r require benefit tax deduction excess recognize compensation cost report statement cash flow finance cash flow operate cash flow sfas r supersede accounting principle board opinion accounting stock issue employee apb amend sfas statement cash flow january adopt provision sfas r require fair value sharebase payment employee director include grant stock option recognize consolidated statement operation apply modify prospective method adoption method permit sfas r require compensation expense record vest nonveste stock option stockbase award begin quarter adoption sfas r accordance modify prospective method prior period amount restate reflect adoption sfas r addition calculate pool excess tax benefit available additional pay capital apic accordance provision sfas r table content gilead sciences inc note consolidated financial statementscontinue december pro forma information sfas prior adoption sfas r accordance provision sfas amend sfas accounting stockbase compensationtransition disclosure elect follow apb fasb interpretation account certain transaction involve stock compensationan interpretation apb opinion accounting employee stockbase plan apb exercise price employee director stock option equal great fair value underlie stock date grant compensation expense recognize consolidated statement operation table present net income basic diluted net income share compensation cost stock option plan espp determine base estimate fair value award plan grant purchase date accordance sfa thousand share amount year end december net incomea report add stockbased employee compensation expense include report net income net relate tax effect deduct total stockbase employee compensation expense determine fair value base method award net relate tax effect net income calculation basicpro forma earning share interest expense makewhole payment convertible debt redemption net income calculation dilutedpro forma earning share net income share basica report basicpro forma diluteda report dilutedpro forma cash cash equivalent consider highly liquid investment insignificant interest rate risk original maturity month purchase date cash equivalent enter overnight repurchase agreement repos purchase security obligation resell follow day security purchase agreement resell record face value report cash cash equivalent investment policy enter repos major bank authorize dealer provide repos collateralize government security fair value fair value security sell gilead eligible instrument investment policy include cash equivalent include commercial paper money market fund bank obligation marketable nonmarketable security determine appropriate classification marketable security consist primarily debt security include auction rate security variable rate demand obligation time purchase reevaluate designation balance sheet date marketable security consider availableforsale carry estimate fair value report cash equivalent shortterm table content gilead sciences inc note consolidated financial statementscontinue december marketable security longterm marketable security unrealize gain loss availableforsale security exclude earning report separate component stockholder equity interest income net include interest dividend amortization purchase premium discount realize gain loss sale security cost security sell base specific identification method regularly review investment otherthantemporary decline fair value review include consideration cause impairment include creditworthiness security issuer number security unrealize loss position severity duration unrealize loss determine decline fair value investment accounting basis otherthantemporary reduce carry value security hold record loss decline result enter collaboration time time hold investment nonpublic company record nonmarketable security cost noncurrent asset amount otherthantemporary impairment regularly review investment indicator impairment investment nonmarketable security material period present concentration risk subject credit risk portfolio cash equivalent marketable security policy limit amount invest security duration industry group investment type issuer security issue government expose significant concentration credit risk financial instrument goal investment policy order priority follow safety preservation principal diversification risk liquidity investment sufficient meet cash flow requirement competitive aftertax rate return subject credit risk account receivable relate product sale majority trade account receivable arise product sale united states europe certain country payment typically slow primarily greece italy portugal spain aggregate account receivable balance significant case slow payment practice country reflect pace governmental entity reimburse customer turn increase financial risk relate certain customer sale customer country tend relatively slow pay past increase future increase average length time account receivable outstanding december past account receivable greece italy portugal spain total million million day past base contractual term receivable december past account receivable country total million million day past base contractual term receivables date experience significant loss respect collection account receivable believe past account receivable net allowance reflect consolidated balance sheet collectible perform credit evaluation customer financial condition generally require collateral certain raw material utilize operation obtain supplier raw material utilize operation facility supplier key component raw material name new drug application nda file food drug administration fda product significant delay occur qualification new supplier require delivery material supplier interrupt reason unable ship truvada viread atripla emtriva hepsera ambisome vistide supply drug candidate clinical trial table content gilead sciences inc note consolidated financial statementscontinue december account receivable trade account receivable record net allowance government chargeback cash discount prompt payment doubtful account sale return estimate government chargeback cash discount sale return base contractual term historical trend expectation utilization rate program estimate allowance doubtful account determine base exist contractual obligation historical payment pattern customer individual customer circumstance analysis day sale outstanding customer geographic region review local economic environment potential impact government funding reimbursement practice historically amount uncollectible account receivable write insignificant consistent management expectation inventory inventory record low cost market cost determine firstin firstout basis periodically review composition inventory order identify obsolete slowmoving unsaleable item unsaleable item observe alternate use inventory record writedown net realizable value period impairment recognize prepay royalty prepay royalty capitalize cost base present value future royalty obligation expect pay licensor expect level product sale incorporate related technology review quarterly expect future sale level product indicator require writedown net recoverable value asset change estimate life prepay royalty amortize prepay royalty cost good sell remain life underlie patent base effective royalty rate derive forecast future product sale incorporate related technology review effective royalty rate annually prospectively adjust effective rate base significant new fact circumstance arise review property plant equipment property plant equipment state cost accumulate depreciation amortization depreciation amortization recognize straightline method land depreciate repair maintenance cost expense incur estimate useful life year follow description estimate useful life building improvement laboratory manufacturing equipment office computer equipment leasehold improvement short useful life lease term office computer equipment include capitalize computer software capitalize software purchase internally develop computer software leasehold improvement capitalize lease equipment amortize short lease term asset useful life amortization capitalize lease equipment include depreciation expense capitalize interest construction inprogress include property plant equipment interest million capitalize significant interest capitalize table content gilead sciences inc note consolidated financial statementscontinue december goodwill intangible asset goodwill represent excess purchase price estimate fair value net asset acquire business combination accordance sfas goodwill intangible asset sfas goodwill amortize require test annually impairment test goodwill impairment annual basis annual test aware event occur change circumstance indicate reduction fair value goodwill carry accordance sfas intangible asset definite life amortize estimate useful life review impairment fact circumstance suggest carry value asset recoverable impairment longlive asset carry value longlive asset review regular basis existence fact circumstance internally externally suggest impairment specific potential indicator impairment include significant decrease fair value asset significant change extent manner asset significant physical change asset significant adverse change legal factor business climate affect value asset adverse action assessment fda regulator accumulation cost significantly excess originally expect acquire construct asset operate cash flow loss combine history operate cash flow loss projection forecast demonstrate continue loss associate incomeproduce asset indication impairment test recoverability compare estimate undiscounted future cash flow expect result use asset eventual disposition carry asset estimate future cash flow asset liability group low level identifiable cash flow largely independent cash flow generate group undiscounte future cash flow carry asset impairment loss measure excess carrying value asset estimate fair value recognize cash flow estimate calculation base management good estimate appropriate customary assumption projection time foreign currency translation transaction contract adjustment result translate financial statement foreign subsidiary dollar exclude determination net income loss accumulate separate component stockholder equity net foreign exchange transaction gain loss include interest income net consolidated statement operation realize gain loss total million million million respectively hedge certain foreign currency exposure related outstanding trade account receivable forecast product sale foreign exchange forward contract general market risk contract offset correspond gain loss transaction hedge exposure credit risk contract function change interest currency exchange rate vary time limit risk counterpartie contract unable perform transact major bank limit risk loss enter contract provide net settlement maturity overall risk loss event counterparty default limit unrecognize unrealized gain outstanding contract ie contract positive fair value date table content gilead sciences inc note consolidated financial statementscontinue december default enter speculative foreign currency transaction presently hedge net investment foreign subsidiary accounting hedge net monetary asset liability record change fair value interest income net derivative instrument designate hedge sfas nos accounting derivative instrument hedge activity collectively refer sfas selectively hedge anticipate currency exposure purchase forward contract hedge anticipate product sale year designate cash flow hedge sfas unrealized gain loss underlie forward contract record comprehensive income loss recognize earning forecast transaction occur december december net unrealize gain loss million million respectively open foreign exchange forward contract gain loss cash flow hedge record product sale increase decrease product sale million million million respectively notional amount forward exchange contract outstanding billion december million december asset liability fair value million million december respectively contract maturity year note discussion derivative financial instrument fair value financial instrument financial instrument consist principally cash cash equivalent marketable security account receivable certain noncurrent asset forward foreign exchange contract account payable longterm debt longterm obligation cash cash equivalent marketable security note forward foreign exchange contract hedge account receivable note report respective fair value balance sheet forward foreign exchange contract hedge forecast sale record fair value net relate deferred gain loss result report net balance zero believe remain financial instrument report consolidated balance sheet amount approximate current fair value income taxis income tax provision compute liability method defer tax asset liability determine base difference financial statement tax basis asset liability enact tax rate effect year difference expect reverse significant estimate require determine provision income tax estimate base interpretation exist tax law regulation believe estimate reasonable reserve income taxrelate uncertainty adequate internal external factor favorable unfavorable effect future effective income tax rate factor include limited interpretation exist tax law adoption sfas r relate accounting stock option sharebase compensation change tax law rate merger acquisition future level research development spending change accounting standard future level capital expenditure change mix earning tax jurisdiction operate change overall level pretax earning finalization federal state income tax audits table content gilead sciences inc note consolidated financial statementscontinue december recent accounting pronouncement june fasb issue fasb interpretation accounting uncertainty income taxis fin interpretation sfas accounting income taxis sfas fin clarifie accounting uncertainty income taxis recognize enterprise financial statement accordance sfas prescribe minimum recognition threshold measurement attribute financial statement recognition measurement tax position take expect take tax return fin provide guidance derecognition measurement classification interest penalty account interim period disclosure transition fin effective fiscal year begin december adopt fin january require preliminary determination impact adopt standard range million million actual record charge accumulate deficit consolidate balance sheet adoption fin derivative financial instrument derivative recognize asset liability measure fair value enter foreign currency forward contract hedge change fair value significant monetary asset liability denominate nonfunctional currency derivative designate meet definition fair value hedge change fair value derivative hedge item recognize earning enter foreign currency forward contract maturity month hedge future cash flow relate forecasted product sale foreign denominate currency derivative instrument employ eliminate minimize certain foreign currency exposure confidently identify quantify hedge relate forecasted foreign currency product sale designate document inception respective hedge designate cash flow hedge evaluate effectiveness monthly term forward contract underlie transaction match inception forward contract effectiveness calculate compare fair value contract estimate change fair value underlie hedged item effective component hedge record accumulate comprehensive income note substantially value report accumulate comprehensive income december reclassify earning month residual change fair value instrument include result cancellation dedesignation hedge contract ineffectiveness recognize immediately interest income net impact ineffectiveness significant consolidated statement operation gain loss million million million hedging contract recognize consolidated statement operation respectively include cash provide operating activity consolidate statement cash flow result enter collaboration arrangement hold warrant purchase stock nonpublic company complete initial public offering january note warrant exercise end quarter acquisition myogen inc november complete acquisition outstanding share common stock myogen cash tender offer term agreement plan merger enter october merger agreement myogen publiclyheld biopharmaceutical company base westminster table content gilead sciences inc note consolidated financial statementscontinue december colorado focus discovery development commercialization small molecule therapeutic treatment cardiovascular disorder myogen product candidate latestage clinical development ambrisentan treatment patient pulmonary arterial hypertension darusentan treatment patient resistant hypertension believe acquisition provide opportunity expand respiratory cardiopulmonary therapeutic area initially establish acquisition corus august myogen acquisition account business combination accordance sfas business combination sfas result operation myogen november include consolidated statement operation primarily consist rd sga expense aggregate purchase price myogen common stock billion consist cash pay prior closing billion fair value vest stock option assume million estimate direct transaction cost million consist primarily investment banking fee employeerelate severance cost million employeerelate severance cost include purchase price establish workforce reduction plan acquisition transaction accordance eitf issue recognition liability connection purchase business combination eitf accordance merger agreement enter myogen conversion value stock option assume determined base exercise price option purchase share common stock myogen average closing price common stock consecutive trading day immediately precede include tender offer acceptance date november share estimate fair value stock option assume determined average price share approximate price resulted average closing price common stock trading day trading day acceptance date accordance eitf issue determination measurement date market price acquirer security issue purchase business combination fair value stock option assume calculate blackschole valuation model follow assumption expect life range year riskfree interest rate range expect volatility range dividend yield fair value asconverte gilead stock option exceed fair value myogen stock option immediately prior exchange approximately million million asconverte share subject outstanding myogen stock option fully vest estimate fair value vest option million include purchase price estimate fair value unvested option million include purchase price recognize compensation expense remain future vest period option table content gilead sciences inc note consolidated financial statementscontinue december follow table summarize preliminary purchase price allocation november thousands cash cash equivalent shortterm marketable security account receivable net prepaid expense asset account payable defer revenue liability net tangible asset defer tax asset purchase inprocess research development goodwill total purchase price million defer revenue reflect fair value defer revenue legal performance obligation accordance eitf issue accounting business combination defer revenue acquiree million defer tax asset primarily related federal net operating loss tax credit carryforward certain state amortization conclude base standard set forth sfas likely realize benefit defer tax asset elect treat myogen acquisition asset acquisition california state tax purpose purchase inprocess research development iprd goodwill result acquisition deductible california state income tax purpose amount deductible federal income tax purpose purchase price allocation preliminary finalized continue review federal net operating loss carryforward available assess tax deductibility certain acquisitionrelate transaction cost accordance sfas eitf issue uncertaintie related income taxis purchase business combination material change preliminary allocation summarize report related uncertainty resolve estimate fair value purchase iprd billion determined management management consider number factor determine value iprd include result independent valuation perform party valuation specialist purchase iprd represent myogen incomplete research development program reach technological feasibility alternative future use acquisition date expense acquisition consolidated statement operation summary iprd program acquisition date follow estimate acquisition date fair value program description status development millions ambrisentan orally active nonsulfonamide propanoic acidclass endothelin phase clinical trial complete prior acquisition date file nda receptor antagonist era treatment pulmonary arterial fda december february fda grant priority review hypertension status nda marketing approval ambrisentan establish target review date june table content gilead sciences inc note consolidated financial statementscontinue december estimate acquisition date fair value program description status development millions darusentan orally active etaselective era treatment resistant phase clinical development acquisition date date filing hypertension estimate fair value purchase iprd determine income approach discount expect future cash flow present value estimate related future net cash flow present value riskadjuste discount rate significant assumption base estimate internal rate return myogen operation comparable estimate weighted average cost capital company myogen profile project cash flow ambrisentan darusentan program base key assumption estimate revenue operate profit relate program consider stage development time resource need complete development approval relate product candidate life potential commercialize product associate risk include inherent difficulty uncertaintie develop drug compound obtain fda regulatory approval risk relate viability potential alternative treatment future target market remain effort completion myogen iprd project primarily consist clinical trial cost length success extremely difficult predict obtain necessary regulatory approval numerous risk uncertainty exist prevent completion development include ability enroll patient clinical trial possibility unfavorable result clinical trial risk fail obtain fda regulatory body approval feedback regulatory authority result clinical trial require modification delay later stage clinical trial additional trial perform certain ambrisentan darusentan purchase myogen approve united states country outside united states marketing approval significant limitation use future discussion regulatory agency determine datum need timeline review differ materially current projection acquire product candidate development successfully commercialize result strategic decision discontinue development product candidate example believe commercialization difficult relative opportunity pipeline program complete timely basis prospect future revenue growth adversely impact assurance give underlie assumption forecast cash flow timely successful completion project materialize estimate reason actual result vary significantly estimate result excess purchase price fair value amount assign asset acquire liability assume million represent goodwill result myogen acquisition record goodwill noncurrent asset consolidated balance sheet acquisition date accordance sfas test goodwill impairment annual basis annual test aware event occur change circumstance indicate reduction fair value goodwill carrying follow unaudited pro forma information present result operation gilead myogen year end december acquisition myogen complete january respectively unaudited pro forma result include nonrecurre charge purchase table content gilead sciences inc note consolidated financial statementscontinue december iprd period present result directly transaction unaudited pro forma result reflect operating efficiency potential cost saving result consolidation operation gilead myogen accordingly unaudite pro forma result present illustrative purpose intend represent indicative actual result operation combine company achieve acquisition occur begin period present intended represent indicative future result operation unaudite pro forma result operation follow thousand share datum year end december total revenue net loss net loss sharebasic diluted raylo chemicals inc november complete acquisition outstanding share common stock raylo chemicals inc raylo whollyowne subsidiary germanybase specialty chemical company degussa ag locate edmonton canada raylos operations encompass custom manufacture active pharmaceutical ingredient api advanced intermediate pharmaceutical biopharmaceutical industry intend utilize raylo site process research scaleup clinical development candidate manufacture api investigational commercial product chemical development activity improve exist commercial manufacturing process raylo acquisition account business combination accordance sfas result operation raylo november include consolidated statement operation primarily consist contract revenue cost good sell clinical api expense aggregate purchase price raylo common stock million consist cash pay prior closing million estimate direct transaction cost million employeerelate severance cost million employeerelate severance cost include purchase price establish workforce reduction plan acquisition transaction accordance eitf cost fully pay december follow table summarize purchase price allocation november thousands net tangible asset gmp qualification intangible asset goodwill total purchase price million net tangible asset include million cash million property plant equipment million tangible asset assume liability million estimate fair value million associate good manufacturing practice gmp qualification raylos facilities determine management base result independent valuation perform table content gilead sciences inc note consolidated financial statementscontinue december thirdparty valuation specialist value record intangible asset amortize straightline basis year estimate useful life asset determine management base time derive benefit make substantial upgrade revision acquire manufacturing practice december accumulate amortization asset million represent amortization expense recognize date acquisition december estimate aggregate amortization expense recognize future year approximately million million excess purchase price fair value amount assign asset acquire liability assume million represent goodwill result raylo acquisition record goodwill noncurrent asset consolidated balance sheet acquisition date accordance sfas test goodwill impairment annual basis annual test aware event occur change circumstance indicate reduction fair value goodwill carrying elect treat raylo acquisition asset acquisition federal california state tax purpose goodwill result acquisition deductible federal california state income tax purpose prior acquisition raylo longstanding contract manufacturer determine accordance eitf issue accounting preexisting relationship party business combination settlement preexist relationship business combination value need assign preexist relationship purchase price allocation summarize raylos assets acquisition date include million trade receivables eliminate consolidated financial statement completion acquisition consider raylo acquisition material business combination sfas disclose pro forma result operation require sfas material business combination corus pharma inc august complete acquisition corus privatelyheld biopharmaceutical company base seattle washington corus development stage company focus development commercialization novel drug respiratory infectious disease corus lead product candidate latestage clinical trial earlystage product candidate acquisition provide opportunity expand respiratory therapeutic area augment pipeline corus acquisition account acquisition asset business combination accordance criterion outline eitf issue determine nonmonetary transaction involve receipt productive asset business sfas corus consider development stage company commence plan principal operation additionally lack necessary element business include complete product ability access customer result operation coru august include consolidated statement operation primarily consist rd expense less extent sga expense april purchase million coruss series c prefer stock represent approximately coruss voting equity interest time conjunction purchase series c table content gilead sciences inc note consolidated financial statementscontinue december prefer stock enter agreement plan merger option acquire merger remain outstanding share corus july announce agree exercise option concurrently enter agreement novartis vaccine diagnostics inc novartis novartis agree dismiss litigation corus payment novartis claim novartis directly implicate coruss right develop commercialize product settle novartis deem appropriate allow completion acquisition ensure claim novartis impede ability develop commercialize corus product candidate settlement result ongoing trial time settlement uncertain sustained period follow close legal appeal potential proceeding completion acquisition include investment coruss series c prefer stock payment novartis acquisition purchase price aggregate purchase price acquire share asset million consist cash pay prior closing million fair value vest stock option assume million estimate direct transaction cost million employeerelate severance cost million addition holdback million payable corus shareholder future extent utilize pay claim year closing merger assess probable pay holdback record accrue liability consolidate balance sheet acquisition date employeerelate severance cost include purchase price establish workforce reduction plan acquisition transaction follow table summarize purchase price allocation august thousand net tangible asset assemble workforce net defer tax asset purchase inprocess research development million net tangible asset include million cash million investment million tangible asset assume liability million million value assign assemble workforce amortize year estimate useful life asset million net defer tax asset primarily related federal net operating loss tax credit carryforward certain state amortization conclude base standard set forth sfas likely realize benefit defer tax asset elect treat corus acquisition asset acquisition california state tax purpose purchase iprd result acquisition deductible california state income tax purpose deductible federal income tax purpose estimate fair value purchase iprd assemble workforce determine management management consider number factor determine value iprd include result independent valuation perform thirdparty valuation specialist estimate fair value purchase iprd great purchase price pay allocate purchase iprd consist net remain allocate purchase price net tangible asset assemble workforce net defer tax asset purchase iprd represent coruss incomplete research table content gilead sciences inc note consolidated financial statementscontinue december development program reach technological feasibility alternative future use acquisition date expense acquisition consolidated statement operation summary program acquisition date follows estimate acquisition date fair value program description status development million inhale aztreonam lysine cystic fibrosis aztreonam formulation inhalation gramnegative phase clinical trial acquisition date date filing bacteria cause lung infection patient cystic fibrosis estimate fair value purchase iprd determine income approach discount expect future cash flow present value estimate related future net cash flow present value riskadjuste discount rate significant assumption base estimate internal rate return coruss operation comparable estimate weighted average cost capital company coruss profile project cash flow aztreonam lysine inhalation program base key assumption estimate revenue operate profit relate program consider stage development time resource need complete development approval relate product candidate life potential commercialize product associate risk include inherent difficulty uncertaintie develop drug compound obtain fda regulatory approval risk relate viability potential alternative treatment future target market coruss earlystage candidate include valuation purchase iprd earlystage project identifiable revenue expense associate remain effort completion coruss iprd project primarily consist clinical trial cost length success extremely difficult predict obtain necessary regulatory approval numerous risk uncertainty exist prevent completion development include ability enroll patient clinical trial possibility unfavorable result clinical trial risk fail obtain fda regulatory body approval feedback regulatory authority result clinical trial require modification delay later stage clinical trial additional trial perform certain aztreonam lysine cystic fibrosis purchase corus approve united states country outside united states marketing approval significant limitation use future discussion regulatory agency determine datum need timeline review differ materially current projection acquire product candidate development successfully commercialize result strategic decision discontinue development product candidate example believe commercialization difficult relative opportunity pipeline program complete timely basis prospect future revenue growth adversely impact assurance give underlie assumption forecast cash flow timely successful completion project materialize estimate reason actual result vary significantly estimate result acquisition real estate august complete purchase additional building locate foster city california campus aggregate purchase price million purchase price allocate table content gilead sciences inc note consolidated financial statementscontinue december land building land improvement base estimate relative fair value determine management base independent appraisal million million million respectively fair value building land improvement depreciate remain useful economic life estimate year asset disposal march receive local city approval proceed demolition building foster city california begin construction new facility include charge associate writeoff building equal aggregate net book value million sga expense gain warrant march enter agreement eyetech pharmaceuticals inc eyetech predecessor osi relate proprietary aptamer eye currently know macugen pursuant agreement receive warrant purchase share eyetech series b convertible prefer stock exercisable price share january eyetech complete initial public offering common stock time adjust carry value warrant estimate fair value result gain million include consolidated statement operation year end december fair value warrant estimate blackschole valuation model volatility discount rate end quarter exercise warrant net basis share eyetech common stock consideration exercise price subsequently hold share eyetech common stock second quarter sell eyetech share hold realize gain million include interest income net consolidated statement operation year end december table content gilead sciences inc note consolidated financial statementscontinue december availableforsale security follow summary availableforsale security record cash equivalent marketable security consolidate balance sheet estimate fair value availableforsale security base price obtain commercial pricing service thousand gross gross amortize unrealize unrealized estimate cost gain loss fair value december debt security treasury security government sponsor entity debt security corporate debt security assetbacke security municipal debt security debt security total debt security equity security total december treasury security obligation government agencie government sponsor entity debt security corporate debt security assetbacke security municipal debt security debt security total december debt security consist primarily money market fund auction rate security follow table present classification availableforsale security consolidate balance sheet december cash cash equivalent shortterm marketable security longterm marketable security total december portfolio availableforsale debt security comprise million security contractual maturity year million security contractual maturity great year year auction rate security aggregate fair value million contractual maturity great year table content gilead sciences inc note consolidated financial statementscontinue december follow table present certain information relate sale marketable security thousand year end december proceed sale gross realize gain sale gross realize loss sale december follow availableforsale debt security continuous unrealized loss position deem otherthantemporarily impair thousand month month great gross gross unrealize estimate unrealized estimate loss fair value loss fair value december treasury security government sponsor entity debt security corporate debt security assetbacke security municipal debt security total december treasury security government sponsor entity debt security corporate debt security assetbacke security municipal debt security total gross unrealized loss cause interest rate increase significant fact circumstance arise indicate deterioration creditworthiness issuer security base review security include assessment duration severity relate unrealized loss ability intent hold investment maturity otherthantemporary impairment security december european headquarters relocation june announce commercial medical administrative group european headquarters base paris france relocate london area united kingdom european headquarters regulatory safety information technology group locate cambridge area united kingdom believe relocation enable achieve efficiency close proximity group position ourself compete large pharmaceutical company global level french subsidiary continue occupy exist paris facility continue maintain expand sale marketing presence france table content gilead sciences inc note consolidated financial statementscontinue december quarter relocation plan finalize accrued charge million primarily consist employee severance cost termination benefit include sga expense december majority severance cost termination benefit pay reduce relocation accrual include accrue compensation employee benefit consolidate balance sheet insignificant additional cost relate new headquarters united kingdom include recruitment cost legal expense capital expenditure relate cost expense incur significant relocation activity complete december aggregate severance relocation recruiting cost result relocation european headquarters approximately million inventory inventory summarize follow thousand december work process raw material finish good total december joint venture form gilead bms include consolidated financial statement hold million million respectively sustiva efavirenz api purchase bms bmss estimate net selling price sustiva market include inventory note establish gilead access program december pursuant agree truvada viread available noprofit price develop country africa caribbean latin america southeast asia base regular evaluation forecast sale pricing inventory shelf life conclude fully recover carrying value associate inventory truvada viread gilead access program result record million year end december cost good sell writedown inventory estimate net realizable value table content gilead sciences inc note consolidated financial statementscontinue december consolidated balance sheet detail thousand december property plant equipment net building improvement include leasehold improvement laboratory manufacturing equipment office computer equipment capitalize lease equipment construction inprogress accumulate depreciation amortization include relate capitalize lease equipment respectively subtotal land total accrue liability accrue medicaid rebate liabilitie total joint venture bristolmyer squibb december enter collaboration bms develop commercialize single tablet regimen truvada bmss sustiva united states structure joint venture bms form limited liability company bristolmyers squibb gilead sciences llc term collaboration bms grant royaltyfree sublicense joint venture use respective companyowne technology return grant license joint venture use intellectual property result collaboration ownership interest joint venture bms reflect respective economic interest base fraction estimate net selling price atripla single tablet regimen attributable truvada sustiva respectively adjust annual basis net selling price truvada change time relative net selling price sustiva gilead bmss respective economic interest joint venture vary annually primary responsibility clinical development activity regulatory filing relate new product result collaboration share marketing sale effort bms party provide equivalent sale force effort minimum number year daily operation joint venture govern primary joint committee responsible accounting financial reporting product distribution joint venture party agree provide respective bulk api joint venture approximate market value april joint venture file nda fda approval atripla treatment hiv infection adult july joint venture receive approval atripla september bms amend joint venture collaboration agreement allow joint venture sell atripla canada december joint venture hold sustiva api purchase bms bmss estimate net selling price sustiva market include inventory consolidated balance sheet note table content gilead sciences inc note consolidated financial statementscontinue december joint venture total equity investment risk expect sufficient allow finance operational activity ongoing funding bms primary beneficiary legal structure joint venture limit recourse creditor general credit asset explain note consolidated financial statement include account joint venture bms reflect bmss minority interest joint venture collaborative arrangement contract result enter strategic collaboration time time hold investment nonpublic company review interest investee company consolidation andor appropriate disclosure provision fin r december determine certain investee company variable interest entity respect joint venture bms primary beneficiary roche september enter development license agreement agreement f hoffmannla roche ltd hoffmannla roche inc roche develop commercialize therapy treat prevent viral influenza tamiflu antiviral oral formulation treatment prevention influenza codevelope roche agreement roche exclusive right manufacture sell tamiflu worldwide subject obligation pay percentage net revenue roche generate tamiflu sale turn subject reduction certain define manufacturing cost june deliver notice termination roche material breach agreement november resolve dispute roche relate breach agreement agree terminate relate arbitration pende party connection dispute resolution enter amendment supplement agreement roche amend agreement provide formation joint manufacturing committee review roche exist manufacturing capacity tamiflu global plan manufacture tamiflu commercial committee evaluate commercial plan strategy tamiflu united states joint supervisory committee evaluate roche overall commercial plan tamiflu global basis case consist representative roche amend agreement option provide specialized sale force supplement roche marketing effort united states tamiflu royalty payable net sale tamiflu sell roche remain amend agreement follow million worldwide net sale give calendar year b million worldwide net sale calendar year c worldwide net sale excess million calendar year amend agreement revise provision agreement relate calculation royalty payment give calendar quarter roche pay royalty base actual royalty rate applicable quarter addition amend agreement royalty payable roche long subject cost good sell adjustment provide agreement roche pay million recognize royalty revenue consist million relate dispute royalty million relate reimbursement cost good adjustment million relate update royalty payable month base thencurrent royalty rate instead prior year effective royalty rate table content gilead sciences inc note consolidated financial statementscontinue december record total million million million tamiflu royalty respectively recognize royalty revenue roche quarter follow quarter relate tamiflu sale occur recognize contract revenue million milestone payment japanese approval tamiflu prophylaxis milestone receivable amend agreement emory university july royalty pharma purchase royalty interest own emory university emory emtricitabine hiv indication term agreement royalty pharma pay respectively total purchase price million emory exchange elimination emtricitabine royalty emory worldwide net sale product contain emtricitabine result transaction capitalize prepaid royalty share million purchase price million amortize prepay royalty cost good sell remain life underlie patent base effective royalty rate derive forecast future product sale million million amortize cost good sell respectively record royalties royalty pharma base actual emtricitabine net sale relative royalty pharma ownership underlie emory royalty interest pay royalty million million royalty pharma respectively july payment million emory connection amendment restatement exist license agreement emory provide great strategic flexibility development emtricitabine hepatitis b indication record payment rd expense expect significant relate rd year prior july pay royalty emory respect emtricitabine hiv indication worldwide license acquire acquisition triangle pharmaceuticals inc triangle pay royalty million million respectively net sale emtricitabine iocbrega enter agreement institute organic chemistry biochemistry academy sciences czech republic rega stichte iocbrega relate certain nucleotide compound discover institution agreement receive exclusive right manufacture use sell nucleotide compound obligate pay iocbrega percentage net revenue receive sale product contain patented compound subject minimum royalty payment product cover original agreement include vistide hepsera viread december agreement iocbrega amend provide reduce royalty rate future sale product contain tenofovir adefovir return upfront payment million signing agreement payment record prepay royalty classified asset consolidate balance sheet prepay royalty recognize royalty expense expect commercial life tenofovir adefovir amortization million payment begin product launch date viread hepsera december million remain amortize august agreement iocbrega amend include truvada future fixeddose combination product contain license technology quarterly payment iocbrega base percentage vistide hepsera viread truvada net sales iocbrega agree waive table content gilead sciences inc note consolidated financial statementscontinue december right royalty sale truvada viread develop country sell product profit gilead access program sale atripla distribute merck co inc develop country pay royalty million million million iocbrega respectively japan tobacco inc july enter licensing agreement japan tobacco inc japan tobacco japan tobacco commercialize product hiv product portfolio japan agreement include viread truvada emtriva term agreement receive upfront license fee million receive additional payment achievement certain milestone japan tobacco pay royalty net sale product japan upfront license fee record defer revenue amortize contract revenue period supply product japan tobacco approximately year remain december receive million year milestone payment japan tobacco relate japanese regulatory approval marketing authorization viread emtriva truvada amortize remaining period upfront license fee march enter licensing agreement japan tobacco japan tobacco grant exclusive right develop commercialize novel hiv integrase inhibitor gs know jtk country world exclude japan japan tobacco retain right term agreement incur upfront license fee million include rd expense quarter future alternative use technology march record million rd expense relate milestone incur result dose patient phase clinical study obligate additional payment achievement milestone pay royalty base future net product sale territory market drug achillion pharmaceutical november enter exclusive license collaboration agreement achillion pharmaceuticals inc achillion term agreement grant worldwide right research development commercialization certain small molecule hepatitic c virus hcv replication inhibitor involve hcv protease treatment hepatitis c collaboration achillion obligate continue development inhibitor compound accord mutually agree development plan completion proofofconcept clinical study hcvinfecte patient cost incur achieve proofofconcept share equally achillion cost incur amount million million respectively follow proofofconcept study obligate assume responsibility incur cost associate development commercialization compound warrant development achillion option participate commercialization effort future product arise collaboration conjunction signing collaboration pay million upfront license fee record rd expense future alternative use license technology additionally invest achillion convertible prefer stock agree payment achillion achievement certain milestone outline agreement pay royalty future net sale product arise collaboration october achillion complete initial public offering convertible preferred stock convert share achillion common stock december investment achillion common stock million record longterm marketable security december achillion begin dose hcvinfecte table content gilead sciences inc note consolidated financial statementscontinue december patient phase clinical study gs know ach treatment hepatitis c february base preliminary datum phase b study company decide discontinue development gs genelabs technologies inc september enter license research collaboration agreement genelabs technologies inc genelabs research develop commercialize certain genelabss novel nucleoside inhibitor hcv polymerase treatment chronic infection cause hcv conjunction signing agreement pay million upfront license fee record rd expense future alternative use technology initially agree term year genelabs obligate lead research effort option extend research term collaboration additional year lead development commercialization activity agree provide annual funding time equivalent million million respectively payment genelabs record rd expense obligate additional payment achievement certain milestone pay royalty future net sale select compound develop approve relation collaboration medarex inc july enter agreement medarex inc medarex medarex buyout future royalty obligation approve product result medarexs licensing patent estate previously hold nexstar inc total agreement million receive installment total million installment total million final installment total million record contract revenue glaxosmithkline inc april enter licensing agreement gsk provide gsk right commercialize hepsera oral antiviral treatment chronic hepatitis b asia latin america certain territory agreement retain right hepsera united states canada europe australia new zealand turkey gsk receive exclusive right develop hepsera solely treatment chronic hepatitis b territory significant include china japan republic korea taiwan receive million milestone payment gsk approval hepsera million milestone payment canadian approval hepsera aggregate million milestone payment commercial approval hepsera japan republic korea taiwan receive aggregate million milestone payment gsk achievement gsk consecutive quarter hepsera gross sale exceed million achievement certain drug status china gsk responsibility development commercialization hepsera territory upfront license fee approval milestone record defer revenue total million million million recognize contract revenue respectively million balance defer revenue december expect amortize contract revenue period supply hepsera gsk agreement approximately year addition gsk require pay royalty net product sale gsk generate sale hepsera epivirhbvzeffix gsk hepatitis product gsk territory begin receive royalty table content gilead sciences inc note consolidated financial statementscontinue december gsk sale hepsera quarter record million million million royalty revenue respectively recognize royalty revenue gsk quarter follow quarter relate hepsera sale occur result acquisition myogen november assume right march license distribution supply agreement myogen gsk term license agreement gsk receive exclusive sublicense right ambrisentan certain hypertensive condition territory outside united states receive upfront payment subject achievement specific milestone eligible receive additional milestone payment addition receive step royalty base net commercial sale ambrisentan gsk territory gsk option negotiate exclusive sublicense additional therapeutic use ambrisentan gsk territory term license agreement continue conduct bear expense clinical development activity believe required obtain maintain regulatory approval ambrisentan united states canada european economic area party conduct additional development activity territory expense party agree jointly develop ambrisentan new indication license field party pay share external cost associate joint development acquisition date myogen record million defer revenue legal performance obligation license agreement amortize deferred revenue contract revenue period performance obligation agreement approximately year term license agreement distribution supply agreement receive exclusive right market promote distribute flolan sterile diluent flolan united states april osi pharmaceuticals inc march enter agreement osi pharmaceuticals inc osi successor eyetech pharmaceuticals inc relate macugen macugen inhibitor vascular endothelial growth factor vegf know play role development certain ophthalmic disease term agreement osi receive worldwide right therapeutic use macugen responsible rd cost entitle receive payment osi osi reach certain milestone royaltie worldwide net sale macugen subject obligation payment party relate royalty february macugen approved european union june recognize million milestone payment osi relate commercial sale macugen european union include contract revenue agreement osi expire later year commercial sale product develop date patent expire agreement additionally receive warrant purchase share eyetech series b convertible prefer stock exercisable price share price stock issue investor note discussion warrant eventual sale eyetech share december enter agreement osi fill finish macugen osi initial term end january record contract revenue million million million respectively connection clinical supply provide osi milestone achieve osi recognize contract revenue million milestone payment osi table content gilead sciences inc note consolidated financial statementscontinue december relate filing new drug application europe united states macugen january osi receive fda approval sale macugen united states astellas pharma inc enter agreement astellas pharma inc astellas successor fujisawa usa inc relate right market ambisome term agreement amend astella responsible promotion ambisome united states astellas sole marketing right ambisome canada exclusive marketing right ambisome rest world subject obligation pay royalty astellas connection sale significant market asia include china india japan republic korea taiwan connection sale astella purchase ambisome manufacturing cost sale canada astellas purchase ambisome manufacturing cost plus specify percentage astella collect payment sale ambisome united states canada receive royalty equal astellass gross profit sale ambisome united states canada gross profit include deduction cost good sell give current effective royalty rate approximately astellass net sale ambisome united states connection agreement record royalty revenue million million million longterm obligation total longterm obligation consist follow thousand december capital lease obligation monthly installment interest rate range convertible senior note longterm loan quarterly installment interest rate libor plus tiere contractual rate total longterm obligation current portion total longterm obligation future minimum payment longterm obligation follow thousand capital lease longterm year end december obligation loan total represent interest total table content gilead sciences inc note consolidated financial statementscontinue december convertible senior note april issue million principal convertible senior note note million principal convertible senior note note collectively note private placement pursuant rule securities act amend note note issue par bear interest rate respectively debt issuance cost million connection issuance note record noncurrent asset amortize interest expense straightline basis contractual term note aggregate principal note sell reflect exercise initial purchaser option purchase additional note cover overallotment note convertible base initial conversion rate share principal note represent initial conversion price approximately share note convertible base initial conversion rate share principal note represent initial conversion price approximately share note convert subject adjustment follow circumstance calendar quarter begin september closing price common stock trading day consecutive trading day period previous quarter applicable conversion price share specified distribution holder common stock specify corporate transaction occur month prior maturity applicable note conversion holder receive cash equal less principal note ii conversion value note conversion value exceed deliver option cash common stock combination cash common stock conversion value excess note convert connection change control require provide makewhole premium form increase conversion rate subject state maximum addition event change control holder require purchase portion note purchase price equal principal note plus accrue unpaid interest thereon december fair value note note approximately million million respectively base quote market value concurrent issuance note purchase convertible note hedge private transaction cost million cover subject customary antidilution adjustment million share common stock strike price correspond initial conversion price note market value share common stock time conversion note strike price applicable convertible note hedge entitle receive counterpartie transaction cash share common stock combination cash common stock option excess market price common stock strike price convertible note hedge convertible note hedge terminate maturity relate note relate note remain outstanding conversion sell warrant acquire million share common stock subject customary antidilution adjustment private transaction receive net proceed million market value common stock time exercise applicable warrant exceed respective strike price require net settle cash share common stock option respective counterpartie value warrant excess warrant strike price maximum number share common stock issue choose net share settle warrant million share underlie share warrant strike price share warrant expire share warrant expire exercisable respective expiration date take convertible note hedge warrant intend reduce potential dilution future conversion note effectively increase initial conversion price share note share note net cost million convertible note hedge warrant transaction record stockholder equity table content gilead sciences inc note consolidated financial statementscontinue december choice settle convertible note hedge warrant cash share stock contract meet applicable criterion equity classification outline eitf issue account derivative financial instrument index potentially settle company stock cost convertible note hedge net proceed sale warrant classify stockholder equity addition contract classify stockholder equity index common stock account derivative sfas record defer tax asset million apic effect future tax benefit relate convertible note hedge accordance sfas eitf income tax consequence issue convertible debt beneficial conversion feature contemporaneously close sale note portion net proceed note issuance proceed warrant transaction repurchase million share common stock million stock repurchase program term note agreement require comply certain covenant december compliance covenant december issue million convertible senior note december note convertible total share common stock share convertible senior note provisionally redeemable option time june specify redemption price plus accrue interest call convertible senior note redemption october issue share common stock note holder conversion november redemption price equal principal note redeem plus accrue unpaid interest redemption date connection redemption makewhole payment million note holder represent equivalent principal value note interest actually pay accrue unpaid date issuance note redemption date conversion million unamortized balance relate debt issuance cost reclassify apic credit facility december enter agreement syndicate bank fiveyear million senior credit facility million facility consist uncollateralized million term loan enter gilead biopharmaceutics ireland corporation gbic whollyowne irish subsidiary uncollateralize million revolve credit facility enter parent company gilead sciences inc proceed term loan gbic december facilitate cash dividend distribution million parent company repatriation qualified foreign earning provision american job creation act ajca term term loan minimum principal payment require repay end calendar quarter begin march percent outstanding balance interest accrue rate libor plus tiere contractual rate basis point payable quarterly arrear gbic prepay term loan accrue interest prepay principal time penalty premium year end december million term loan principal repay outstanding interest principal december payable demand parent company whollyowne subsidiary gilead vintage park llc guarantor december outstanding principal term loan million table content gilead sciences inc note consolidated financial statementscontinue december term revolve credit facility interest accrue payable rate libor plus tiere contractual rate basis point payable quarterly arrear parent company prepay outstanding borrowing accrue interest prepay principal time penalty premium outstanding interest principal december payable demand capacity revolve credit facility increase maximum million term loan repay ability irrevocably cancel unutilized portion revolve credit facility proceed obtain revolve credit facility expect work capital capital expenditure general corporate purpose include issuance letter credit million gilead vintage park llc guarantor december revolve credit facility increase million result cumulative principal repayment million term loan december borrowing revolve credit facility january receive waiver noncompliance total debt total capitalization financial covenant year end december contain credit agreement underlie million credit facility acquisition relate iprd charge billion record fourth quarter purchase iprd cause comply financial covenant concurrent waiver prospectively amend credit agreement exclude iprd charge record commencing october definition total consolidated stockholder equity calculation total capitalization total debt total capitalization ratio contain credit agreement commitment contingency lease arrangement enter longterm noncancelable operating lease equipment facility facility lease san dimas california durham north carolina westminister colorado seattle washington dublin area ireland london area united kingdom expire date durham lease sevenyear renewal option westminister lease fiveyear renewal option lease ireland united kingdom year respectively rent subject increase fifth anniversary respective commencement date operate lease sale marketing administrative facilities europe canada australia term equipment lease include corporate aircraft vary term provide renewal option expiration lease term lease expense operating lease total approximately million million million aggregate noncancelable future minimum rental payment operating lease year end december follow thousand table content gilead sciences inc note consolidated financial statementscontinue december legal proceeding number state county municipality file complaint allege large number pharmaceutical company defendant include gilead instance report inaccurate price product cause governmental entity name plaintiff overpay pharmaceutical product furnish participant medicaid program separate action file new york city numerous new york county consolidate multidistrict litigation proceeding united states district court district massachusetts august case voluntarily dismiss respect gilead august october similar action state alabama v abbott laboratories inc et al currently pende circuit court montgomery county alabama state mississippi v abbott laboratories inc et al currently pende chancery court judicial district hinds county mississippi voluntarily dismiss respect gilead knowledge name additional case county erie v abbott laboratories inc et al currently pende supreme court state new york county erie county oswego v abbott laboratories inc et al currently pende supreme court state new york county oswego county schenectady v abbott laboratories inc et al currently pende supreme court state new york county schenectady complaints assert claim state law seek damage case treble damage attorney fee intend defend case vigorously case preliminary stage possible predict outcome amount accrue relate outcome case united states district court northern district california execute order dismiss entirety prejudice fourth consolidated amend complaint associate purport class action lawsuit gilead chief executive officer chief financial officer executive vice president operation executive vice president research development senior vice president manufacture senior vice president research allege defendant violate federal security law specifically section b securities exchange act amend rule b promulgate securities exchange commission make certain allege false misleading statement plaintiff appeal dismissal september receive service amend complaint add defendant colahan v ward et al case file superior court district columbia plaintiff action misdiagnose hiv participate emtricitabine clinical trial allege negligent conduct clinical trial seek damage defendant jointly severally deny liability intend defend action vigorously case preliminary stage possible predict outcome amount accrue relate outcome case november receive subpoena united states attorney office san francisco request document market medical education program truvada viread emtriva intend comply attorney subpoena cooperate relate government investigation party legal action arise ordinary course business believe legal action material adverse impact business consolidate result operation financial position table content gilead sciences inc note consolidated financial statementscontinue december commitment contingency normal course business enter firm purchase commitment api inventoryrelate item december consist follow year million million million million million stockholder equity stock repurchase program march board directors board authorize program repurchase common stock billion year period stock repurchase program open market private block transaction pursuant rule b plan privately negotiate purchase mean include accelerated stock repurchase transaction similar arrangement time actual number share repurchase depend variety factor include price corporate regulatory requirement market condition april repurchase retire million share common stock share aggregate million remain authorize stock repurchase stock repurchase program terminate march million use par value method accounting stock repurchase par value method common stock charge par value share involve excess cost share acquire par value allocate apic base estimate average sale price issue share excess amount charge accumulate deficit result stock repurchase april reduce common stock apic million retain earning million preferred stock share authorize preferred stock issuable series board authorize determine designation power preference right series increase number share prefer stock potential issuance november right agreement chasemellon shareholder services llc amend right plan prefer stock outstanding december december right agreement right plan provide distribution prefer stock purchase right dividend share common stock purchase right currently exercisable certain condition involve acquisition propose acquisition person group common stock purchase right permit holder holder purchase common stock discount market price time payment specify exercise price purchase right addition event certain business combination purchase right permit purchase common stock acquirer discount market price time certain condition purchase right redeemed board price purchase right purchase right voting privilege attach automatically trade common stock october october board approve amendment right plan amendment provide thing increase exercise price right plan extension term plan november october second table content gilead sciences inc note consolidated financial statementscontinue december amendment provide thing increase exercise price right plan extension term right plan october amendment clarify amendment enter connection increase number share prefer stock potential issuance right plan stock option plan stockholder approve adopt equity incentive plan plan stock option nexstar pharmaceuticals inc nexstar triangle corus myogen stock option plan assume result acquisition nexstar triangle corus myogen convert option purchase common stock effective closing acquisition plan broadbase incentive plan allow award grant employee director consultant plan provide option grant designate nonqualifie incentive stock option prior january grant nonqualified incentive stock option stock option grant january nonqualified stock option plan employee stock option generally vest year exercisable period exceed contractual term year date stock option issue grant price fair value common stock grant date stock option exercise settle newly issue common stock plan previously authorize available pool share stockholder approve increase additional number share common stock available issuance plan assume coruss stock plan corus plan conjunction acquisition corus option pursuant corus plan issue outstanding august convert option purchase approximately share common stock remain subject original term condition assume myogen equity incentive plan stock plan collectively myogen plan conjunction acquisition myogen option issue outstanding myogen plan november convert option purchase approximately million share common stock remain subject original term condition share available future grant corus myogen plan december million share remain available future grant plan follow table summarize activity gilead nexstar triangle corus myogen stock option plan option grant present table exercise price fair value underlie common stock grant date share thousand year end december weight weight weight average average average exercise exercise exercise share price share price share price outstanding beginning year grant assume forfeit exercise outstanding end year exercisable end year weight average grant date fair value table content gilead sciences inc note consolidated financial statementscontinue december follow summary stock option outstanding stock option exercisable december option aggregate intrinsic value thousands option outstanding option exercisable weighted weight average average remain weighted remain weight contractual average aggregate contractual average aggregate option life exercise intrinsic option life exercise intrinsic range exercise price outstanding year price value exercisable year price value total total intrinsic value option exercise year end december million million million respectively employee stock purchase plan employee stock purchase plan espp employee purchase share common stock base percentage compensation subject certain limit purchase price share equal low fair value common stock offering date purchase date twoyear lookback feature espp cause offer period reset fair value common stock purchase date original offering date espp purchase employee settle newly issue common stock espps previously authorize available pool share total million share common stock reserve issuance espp december million share remain available issuance espp restrict stock follow summary activity relate nonveste restrict stock award year end december weight average grant date fair share value nonveste january grant forfeit vested nonveste december total fair value share vest year end december million million respectively table content gilead sciences inc note consolidated financial statementscontinue december stockbased compensation january adopt provision sfas r require fair value sharebase payment employee director include grant stock option recognize consolidated statement operation apply modify prospective method adoption sfas r stockbased compensation recognize expense requisite service period consolidated statement operation grade vest expense attribution approach nonveste stock option grant prior adoption sfas r straightline expense attribution approach stock option grant adoption sfas r stockbase compensation expense relate stock option recognize adoption sfas r base award ultimately expect vest gross expense reduce estimate forfeiture sfas r require forfeiture estimate time grant revise necessary subsequent period actual forfeiture differ estimate estimate forfeiture base historical experience prior adoption sfas r pro forma information require sfas include forfeiture occur result adoption sfas r recognize benefit stockbase compensation apic incremental tax benefit realize tax attribute currently available utilize addition elect account indirect benefit stockbase compensation research tax credit extraterritorial income deduction consolidate statement operation apic table summarize impact adopt sfas r effective january thousand share amount year end december cost good sell research development expense sell general administrative expense stockbase compensation expense include total cost expense tax benefit relate stockbase compensation expense stockbase compensation expense include net loss stockbase compensation expense include net loss share basic diluted year end december capitalize million stockbase compensation cost inventory total fair value stock option vested year end december million december stockbase compensation expense million relate nonveste stock option award recognize expect recognize estimate weighted average period year valuation assumption fair value award grant stock option plan espp estimate grant purchase date blackschole option valuation model blackschole option valuation model develop use estimate fair value trade option vest restriction fully transferable table content gilead sciences inc note consolidated financial statementscontinue december addition option valuation model require input highly subjective assumption include expect stock price volatility expect award life connection adoption sfas r refine methodology derive valuation model assumption calculate estimate fair value award follow assumption year end december expect volatility stock option espp expect life year stock option espp riskfree interest rate stock option espp expect dividend yield fair value stock option grant prior adoption sfas r calculate multiple option approach fair value stock option grant begin january calculate single option approach prior adoption sfas r historical stock price volatility connection blackschole option valuation model connection adoption sfas r determined blend historical volatility imply volatility trade option common stock well reflection expect volatility expect life stockbase award represent weightedaverage period award expect remain outstanding estimate weightedaverage expect life base historical cancellation historical exercise datum relate stock option contractual term vest term award riskfree interest rate base observe interest rate appropriate term stockbase award dividend yield base history expectation dividend payout comprehensive income loss comprehensive income loss comprise net income loss certain change stockholder equity exclude net income loss change fair value outstanding effective cash flow hedge change unrealize gain loss availableforsale security change cumulative foreign currency translation account comprehensive income loss year end december include consolidated statement stockholder equity component comprehensive income loss show net relate taxis underlie asset liability hold jurisdiction expect generate future tax benefit liability table content gilead sciences inc note consolidated financial statementscontinue december follow reclassification record connection net realize gain loss sale security cash flow hedge previously include comprehensive income loss thousands year end december net unrealized gain loss relate availableforsale security net tax provision benefit respectively net unrealized gain loss relate cash flow hedge net tax provision benefit respectively reclassification adjustment net tax benefit respectively comprehensive income loss balance accumulate comprehensive income net taxis report consolidated balance sheet consist follow component thousand year end december net unrealized gain loss availableforsale security net unrealize gain loss cash flow hedge net foreign currency translation gain accumulate comprehensive income disclosure segment enterprise related information operate business segment primarily focus development commercialization human therapeutic life threaten disease product include segment major product truvada viread atripla emtriva hepsera ambisome account substantially total product sale year end december similar economic characteristic include nature product production process type customer distribution method regulatory environment product sale consist follow thousands year end december hiv product truvada viread atripla emtriva total hiv product sale hepsera ambisome total product sale table content gilead sciences inc note consolidated financial statementscontinue december follow table summarize total revenue external customer collaboration partner geographic region thousand product sale productrelate contract revenue attribute country base shipto location royalty nonproduct relate contract revenue attribute country base location collaboration partner certain revenue amount reclassify geographic region conform current period presentation year end december united states outside united states switzerland france spain united kingdom italy germany european country country total revenue outside united states total revenue december net book value property plant equipment million approximately asset locate united states december net book value property plant equipment united states canada million million respectively represent total net book value property plant equipment follow table summarize revenue customer individually account total revenue total revenue year end december cardinal health inc mckesson corp f hoffmannla roche ltd amerisourcebergen corp table content gilead sciences inc note consolidated financial statementscontinue december income taxis provision income taxis consist follow thousands year end december federal current deferred state current defer foreign current defer provision income taxis foreign pretax income million million million respectively cumulative unremitted foreign earning consider permanently invest outside united states taxis provide approximately million million december respectively residual tax liability amount remit approximately million million december respectively difference provision income taxis compute apply federal statutory income tax rate income loss provision income taxis follow thousands year end december income loss provision income taxis tax federal statutory rate state taxis net federal benefit foreign earning different rate inprocess rd charge research credit net unbenefitted stock compensation benefit qualified foreign earning repatriation benefit loss change valuation allowance provision income taxis table content gilead sciences inc note consolidated financial statementscontinue december defer income taxis reflect net tax effect temporary difference carry amount asset liability financial reporting purpose amount income tax purpose significant component defer tax asset liability follow thousands year end december defer tax asset net operating loss carryforward convertible note hedge capitalize intangible research credit carryforward reserve accrual currently deductible stockbase compensation depreciation relate capitalize rd expense net total defer tax asset valuation allowance valuation allowance total defer tax asset defer tax liability unremitte foreign earning total defer tax liability net defer tax asset valuation allowance million million december december respectively valuation allowance increase decrease million million million year end december respectively conclude base standard set forth sfas likely realize benefit defer tax asset relate certain state net operating loss carryforward release million valuation allowance credit goodwill december federal net operating loss carryforward approximately million federal net operating loss carryforward expire date utilize federal tax credit carryforward approximately million expire utilize addition state net operating loss tax credit carryforward approximately million million respectively valuation allowance million provide state net operating loss tax credit carryforward expire date respectively utilize utilization net operating loss tax credit subject annual limitation ownership change limitation provide internal revenue code amend similar state provision annual limitation result expiration net operating loss credit utilization table content gilead sciences inc note consolidated financial statementscontinue december defer tax asset relate tax benefit employee stock option grant reduce reflect exercise exercise result tax deduction excess previously record benefit base option value time grant additional tax benefit credit apic pursuant sfas r october ajca sign law ajca allow deduction certain qualified foreign earning repatriate define ajca elect apply provision qualify earning repatriation fiscal earning repatriation result onetime tax benefit approximately million include reversal defer tax liability previously accrue unremitted foreign earning million december internal revenue service irs commence examination income tax return tax year believe position comply applicable law record liability base sfas accounting contingency event occur indicate payment amount unnecessary reversal liability result tax benefit recognize period determine liability long necessary estimate tax liability prove ultimate assessment charge expense result believe provide adequate accrual anticipate tax audit adjustment base estimate extent additional taxis interest defer compensation plan maintain retirement saving plan eligible employee defer compensation income tax purpose section k internal revenue code gilead plan gilead plan employee contribute eligible annual compensation subject irs plan limit match contribution gilead plan contribute employee contribution annual maximum match increase total matching contribution expense gilead plan million million maintain deferred compensation plan director officer defer compensation income tax purpose defer compensation plan nonqualifie defer compensation plan subject qualification requirement section internal revenue code compensation defer december subject requirement section internal revenue code plan officer contribute annual salary annual bonus director contribute annual retainer fee amount defer participant deposit rabbi trust record noncurrent asset consolidate balance sheet begin director elect receive portion annual cash retainer phantom share give participant right receive equal value specify number share specify period time payable share gilead common stock partial share pay cash establish plan administrator december phantom share outstanding participant elect distribution date available plan receive defer compensation payment table content gilead sciences inc note consolidated financial statementscontinue december quarterly result operation unaudite follow amount thousand share amount st quarter nd quarter rd quarter th quarter total revenue gross profit product sale total cost expense net income loss net income loss sharebasic net income loss sharedilute total revenue gross profit product sale total cost expense net income net income sharebasic net income sharedilute fourth quarter recognize billion charge purchase iprd associate acquisition quarter recognize acquisitionrelate charge million purchase iprd fourth quarter recognize million royalty revenue relate resolution dispute roche fourth quarter record onetime tax benefit million relate repatriation qualified foreign earning ajca reclassify million million million million foreign exchange transaction gain loss fair value change derivative instrument sga expense interest income net second fourth quarter respectively table content gilead sciences inc schedule ii valuation qualifying account balance addition balance begin charge end period expense deduction period year end december account receivable allowance valuation allowance defer tax asset year end december account receivable allowance valuation allowance defer tax asset year end december account receivable allowance valuation allowance defer tax asset allowance doubtful account sale return cash discount chargeback valuation allowance defer tax asset include million relate acquisition table content